

Barb  
only  
please

Access DB# 93043

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: Duwayne C. Jones  
Art Unit: 1614 Phone Number 308-4634  
Serial Number: 10/025,521  
Mail Box and Bldg/Room Location: 2007, CM1  
Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need. me

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: see attached sheet

Inventors (please provide full names):

Earliest Priority Filing Date: 11

\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please search claims 1, 2 and 3

to be kept

Point of Contact:  
Barb O'Bryen  
Technical Information Specialist  
STIC CM1 6A05 308-4291

RECEIVED  
MAY 2 2003  
STIC

STAFF USE ONLY

Searcher: 1005B	Type of Search	Vendors and cost where applicable
Searcher Phone #:	NA Sequence (#)	STN 331
Searcher Location:	AA Sequence (#)	Dialog
Date Searcher Picked Up:	Structure (#) 2	Questel/Orbit
Date Completed: 5-8-03	Bibliographic	Dr.Link
Searcher Prep & Review Time: 20	Litigation	Lexis/Nexis
Clerical Prep Time:	Fulltext	Sequence Systems
Online Time: 16	Patent Family	WWW/Internet
	Other	Other (specify)

**THIS PAGE BLANK (USPTO)**

=> fil reg; d stat que 13

FILE 'REGISTRY' ENTERED AT 14:53:27 ON 08 MAY 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 MAY 2003 HIGHEST RN 511508-58-0

DICTIONARY FILE UPDATES: 6 MAY 2003 HIGHEST RN 511508-58-0

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003


Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

L1 STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC I

NUMBER OF NODES IS 9

STEREO ATTRIBUTES: NONE

L3 4706 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED 12272 ITERATIONS

4706 ANSWERS

SEARCH TIME: 00.00.01

=> d que nos 114

L1 STR

L3 4706 SEA FILE=REGISTRY SSS FUL L1

L14 0 SEA FILE=REGISTRY ABB=ON L3 AND EMBASE/LC *- no refs in em base*

=> fil capl; d que nos 18; d que nos 110; s 18 or 110

FILE 'CAPLUS' ENTERED AT 15:00:59 ON 08 MAY 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 May 2003 VOL 138 ISS 19  
FILE LAST UPDATED: 7 May 2003 (20030507/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
L1          STR
L3          4706 SEA FILE=REGISTRY SSS FUL L1
L4          546 SEA FILE=CAPLUS ABB=ON L3
L5          3260 SEA FILE=CAPLUS ABB=ON HEADACHE/CT
L6          2815 SEA FILE=CAPLUS ABB=ON MIGRAINE?/OBI
L7          1293 SEA FILE=CAPLUS ABB=ON ANTIMIGRAINE/OBI
L8          5 SEA FILE=CAPLUS ABB=ON L4 AND (L5 OR L6 OR L7)
```

```
L1          STR
L3          4706 SEA FILE=REGISTRY SSS FUL L1
L4          546 SEA FILE=CAPLUS ABB=ON L3
L9          21007 SEA FILE=CAPLUS ABB=ON POTASSIUM(L)CHANNEL#/OBI
L10         3 SEA FILE=CAPLUS ABB=ON L4 AND L9
```

L40. 6 L8 OR L10

=> fil uspatf; d que nos 123

FILE 'USPATFULL' ENTERED AT 15:00:59 ON 08 MAY 2003  
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 6 May 2003 (20030506/PD)  
FILE LAST UPDATED: 6 May 2003 (20030506/ED)  
HIGHEST GRANTED PATENT NUMBER: US6560778  
HIGHEST APPLICATION PUBLICATION NUMBER: US2003084495  
CA INDEXING IS CURRENT THROUGH 6 May 2003 (20030506/UPCA)  
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 6 May 2003 (20030506/PD)  
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2003  
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2003

```
>>> USPAT2 is now available. USPATFULL contains full text of the    <<<
>>> original, i.e., the earliest published granted patents or      <<<
>>> applications. USPAT2 contains full text of the latest US       <<<
>>> publications, starting in 2001, for the inventions covered in   <<<
>>> USPATFULL. A USPATFULL record contains not only the original    <<<
>>> published document but also a list of any subsequent            <<<
```

>>> publications. The publication number, patent kind code, and <<<  
>>> publication date for all the US publications for an invention <<<  
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<  
>>> records and may be searched in standard search fields, e.g., /PN, <<<  
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<  
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<  
>>> enter this cluster. <<<  
>>> <<<

>>> Use USPATALL when searching terms such as patent assignees, <<<  
>>> classifications, or claims, that may potentially change from <<<  
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

L1 STR  
L3 4706 SEA FILE=REGISTRY SSS FUL L1  
L12 1394 SEA FILE=REGISTRY ABB=ON L3 AND USPATFULL/LC  
L18 167 SEA FILE=USPATFULL ABB=ON L12  
L19 12803 SEA FILE=USPATFULL ABB=ON HEADACHE# OR MIGRAINE# OR ANTIMIGRAI  
NE# OR STATUS MIGRAINOSUS OR HEMICRANIA  
L20 1352 SEA FILE=USPATFULL ABB=ON (HEADACHE# OR MIGRAINE# OR ANTIMIGRA  
INE# OR STATUS MIGRAINOSUS OR HEMICRANIA)/IT  
L21 2313 SEA FILE=USPATFULL ABB=ON POTASSIUM(3A)CHANNEL?  
L22 639 SEA FILE=USPATFULL ABB=ON (POTASSIUM(3A)CHANNEL?)/IT  
L23 13 SEA FILE=USPATFULL ABB=ON L18 AND (L19 OR L20 OR L21 OR L22)

=> dup rem 140,123

FILE 'CAPLUS' ENTERED AT 15:01:10 ON 08 MAY 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 15:01:10 ON 08 MAY 2003  
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)  
PROCESSING COMPLETED FOR L40  
PROCESSING COMPLETED FOR L23

L41 18 DUP REM L40 L23 (1 DUPLICATE REMOVED)  
ANSWERS '1-6' FROM FILE CAPLUS  
ANSWERS '7-18' FROM FILE USPATFULL

=> d ibib abs hitstr 1-18

L41 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2003 ACS DUPLICATE 1  
ACCESSION NUMBER: 2002:696658 CAPLUS  
DOCUMENT NUMBER: 137:210975  
TITLE: Modulators of KCNQ potassium  
channels and use thereof in treating  
migraine and mechanistically related diseases  
INVENTOR(S): Dworetzky, Steven I.; Gribkoff, Valentin K.; Kinney,  
Gene G.; Hewawasam, Piyasena  
PATENT ASSIGNEE(S): USA  
SOURCE: U.S. Pat. Appl. Publ., 22 pp.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

US 2002128277	A1	20020912	US 2002-75703	<del>20020214</del>
WO 2002072088	A2	20020919	WO 2002-US4374	20020214

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

## PRIORITY APPLN. INFO.:

US 2001-269967P P 20010220

AB Comps. which function as modulators, particularly, openers, of human KCNQ potassium channel proteins or polypeptides, particularly, central nervous system (CNS)-located KCNQ potassium channels, and heteromultimers thereof, and their use in the treatment of migraine are provided by the present invention. One novel type of potassium channel polypeptide openers provided by the present invention is the fluoroindole compds., described for the first time as therapeutics for the treatment of migraine by preventing the asynchronous firing of neurons. Other KCNQ potassium channel opener compds. that are also useful in the treatments of the invention include 2,4-disubstituted pyrimidine-5-carboxamide derivs. One or more of the compds. according to the present invention may be utilized alone, in combination, or in conjunction with other treatment modalities for reducing, ameliorating and/or alleviating migraine or diseases similar to, or mechanistically related to, migraine, e.g., cluster headache.


## IT 452096-91-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(modulators of KCNQ **potassium channels** and use thereof in treating **migraine** and mechanistically related diseases)

RN 452096-91-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-(1-pyrrolidinyl)-4-(trifluoromethyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



L41 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:964146 CAPLUS

DOCUMENT NUMBER: 138:39187

TITLE: Preparation of piperidinecarboxylates and related compounds as NMDA NR2B receptor antagonists for the treatment or prevention of migraine.

INVENTOR(S): Allen, Christopher; Koblan, Ken S.; Sleeth, Timothy

PATENT ASSIGNEE(S): Merck &amp; Co., Inc., USA

SOURCE: PCT Int. Appl., 185 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

*bad late*

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002100352	A2	20021219	WO 2002-US21069	20020607
WO 2002100352	A3	20030327		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-297672P P 20010612

AB A method for treating or preventing migraines comprises administration of an NR2B receptor antagonist (no data). The invention also encompasses the combination of an NR2B antagonist with a cyclooxygenase-2 selective inhibitor, a calcitonin gene-related peptide receptor (CGRP) ligand, a leukotriene receptor antagonist, or a 5HT1B/1D agonist for the treatment or prevention of migraines. Thus, 4-hydroxybenzoic acid, 1-hydroxybenzotriazole hydrate, benzyl 4-(aminomethyl)piperidine-1-carboxylate (prepn. given), and Et3N in DMF were treated with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and the mixt. allowed to stir at room temp. for 18 h to give 4-[(4-hydroxybenzoylamino)methyl]piperidine-1-carboxylic acid benzyl ester.

IT 471249-73-7P 471250-35-8P 471250-45-0P


471250-46-1P 478552-66-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of piperidinecarboxylates and related compds. as NR2B receptor antagonists for the treatment or prevention of migraine)


RN 471249-73-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[5-pyrimidinylcarbonyl)amino]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 471250-35-8 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 471250-45-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-amino-N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 471250-46-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-amino-N-[[1-[[2-(4-methylphenyl)ethyl]sulfonyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 478552-66-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-amino-N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

IT 471254-11-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of piperidinecarboxylates and related compds. as NR2B receptor antagonists for the treatment or prevention of **migraine**)

RN 471254-11-2 CAPLUS

CN Carbamic acid, [5-[[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]amino]carbonyl]-2-pyrimidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





L41 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:813909 CAPLUS

DOCUMENT NUMBER: 137:325416

TITLE: Preparation of substituted imidazoles/oxazoles/thiazoles as large conductance calcium-activated K channel openers

INVENTOR(S): Hongu, Mitsuya; Hosaka, Toshihiro; Kashiwagi, Toshihiko; Kono, Rikako; Kobayashi, Hiroyuki

PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan

SOURCE: PCT Int. Appl., 302 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083111	A2	20021024	WO 2002-JP3723	<u>20020415</u>
W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CO, CR, CU, CZ, DM, DZ, EC, EE, GE, HR, HU, ID, IL, IN, IS, JP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SG, SI, SK, TN, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			JP 2001-116436	A 20010416
			JP 2001-249671	A 20010820
OTHER SOURCE(S):		MARPAT 137:325416		
GI				



AB The title compds. [I; X = NR<sub>4</sub>, O, S; R<sub>1</sub>, R<sub>2</sub> = H, halo, CO<sub>2</sub>H, etc.; R<sub>3</sub> = aryl, heterocyclyl, alkyl; R<sub>4</sub> = H, alkyl], useful in the prophylaxis and/or treatment for pollakiuria or urinary incontinence, were prepd. Thus, reacting 5-ethyl-2-iodo-4-(3-pyridyl)imidazole with 3-(hydroxymethyl)thiophene-2-boric acid in the presence of Pd(PPh<sub>3</sub>)<sub>4</sub> and aq. 2M Na<sub>2</sub>CO<sub>3</sub> in dimethoxyethane afforded I.2HCl [X = NH; R<sub>1</sub> = Et; R<sub>2</sub> = 3-pyridyl; R<sub>3</sub> = 3-(hydroxymethyl)thien-2-yl] which showed 100% inhibition time of 10-20 min in test on the rhythmic bladder contractions induced by substance P in anesthetized rats.

IT 473693-46-8P 473693-49-1P 473693-52-6P


473693-54-8P 473693-62-8P 473693-64-0P  
473693-71-9P 473693-72-0P 473693-74-2P  
473693-82-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(prepn. of imidazoles/oxazoles/thiazoles as large conductance  
calcium-activated K channel openers)


RN 473693-46-8 CAPLUS

CN Benzeneacetic acid, 4-chloro-.alpha.-[[[2-(dimethylamino)-5-  
pyrimidinyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 473693-49-1 CAPLUS

CN 2-Thiopheneacetic acid, 5-chloro-.alpha.-[[[2-(dimethylamino)-5-  
pyrimidinyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 473693-52-6 CAPLUS

CN 3-Thiopheneacetic acid, .alpha.-[[[2-(dimethylamino)-5-  
pyrimidinyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 473693-54-8 CAPLUS

CN 2-Thiopheneacetic acid, .alpha.-[[[2-(dimethylamino)-5-  
pyrimidinyl]carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 473693-62-8 CAPLUS

CN 3-Thiophenebutanoic acid, .gamma.-[[[2-(dimethylamino)-5-pyrimidinyl]carbonyl]amino]-.beta.-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 473693-64-0 CAPLUS

CN 2-Thiophenebutanoic acid, .gamma.-[[[2-(dimethylamino)-5-pyrimidinyl]carbonyl]amino]-.beta.-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 473693-71-9 CAPLUS

CN 2-Thiophenebutanoic acid, 5-chloro-.gamma.-[[[2-(dimethylamino)-5-pyrimidinyl]carbonyl]amino]-.beta.-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 473693-72-0 CAPLUS

CN Benzenebutanoic acid, 4-chloro-.gamma.-[[[2-(dimethylamino)-5-pyrimidinyl]carbonyl]amino]-.beta.-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 473693-74-2 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[2-(4-chloro-3-fluorophenyl)-2-oxoethyl]-2-(methylthio)- (9CI) (CA INDEX NAME)



RN 473693-82-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-(methylthio)- (9CI) (CA INDEX NAME)



L41 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:793427 CAPLUS

DOCUMENT NUMBER: 137:310932

TITLE: Preparation of N-substituted nonaryl heterocyclyl amides as NMDA/NR2B antagonists for relieving pain

INVENTOR(S): Liverton, Nigel J.; Butcher, John W.; McIntyre, Charles J.; Claiborne, Christopher F.; Claremon, David A.; McCauley, James A.; Romano, Joseph J.; Thompson, Wayne; Munson, Peter M.

PATENT ASSIGNEE(S): Merck &amp; Co., Inc., USA

SOURCE: PCT Int. Appl., 270 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002080928	A1	20021017	WO 2002-US10269	20020402
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,				

UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,  
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-281166P P 20010403

OTHER SOURCE(S): MARPAT 137:310932

GI



AB The title compds. [I; NonAr = nonarom. 5-7 membered contg. heteroatoms; A = (un)substituted Ph, pyrrolyl, imidazolyl, etc.; B = aryl(CH<sub>2</sub>)<sub>0-3</sub>(CH<sub>2</sub>)<sub>0-2</sub>CO, heteroaryl(CH<sub>2</sub>)<sub>1-3</sub>(CH<sub>2</sub>)<sub>0-2</sub>CO, etc.; X = H, OH, F, etc.] which are effective as NMDA NR2B antagonists useful for relieving pain, were prepd. E.g., a 2-step synthesis of II, starting with 4-aminomethylpiperidine, was given. The compds. I exhibit IC<sub>50</sub>'s of less than 50 .mu.M in the FLIPR and binding assays, and thus they have been found to exhibit biol. activity as NMDA NR2B antagonists.

IT 471249-73-7P 471250-35-8P 471250-45-0P


471250-46-1P 471252-05-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of N-substituted nonaryl heterocyclyl amides as NMDA/NR2B antagonists for relieving pain)


RN 471249-73-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[5-pyrimidinylcarbonyl)amino]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 471250-35-8 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 471250-45-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-amino-N-[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 471250-46-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-amino-N-[[1-[[2-(4-methylphenyl)ethyl]sulfonyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 471252-05-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[(4-amino-1,2-dihydro-2-oxo-5-pyrimidinyl)carbonyl]amino]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




IT 471254-11-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of N-substituted nonaryl heterocyclyl amides as NMDA/NR2B antagonists for relieving pain)

RN 471254-11-2 CAPLUS

CN Carbamic acid, [5-[[[1-[(2-phenylethyl)sulfonyl]-4-piperidinyl]methyl]amino]carbonyl]-2-pyrimidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 2002:657952 CAPLUS  
 DOCUMENT NUMBER: 137:185506  
 TITLE: Preparation of 2,4-disubstituted pyrimidine-5-carboxamides as KCNQ potassium channel modulators  
 INVENTOR(S): Hewawasam, Piyasena; Dodd, Dharmpal S.; Weaver, Charles D.; Dextraze, Pierre; Gribkoff, Valentin K.; Kinney, Gene G.; Dworetzky, Steven I.  
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA  
 SOURCE: PCT Int. Appl., 54 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

*applicant priority del*

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002066036	A1	20020829	WO 2002-US4305	20020214
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002183335	A1	20021205	US 2002-75521	20020214
PRIORITY APPLN. INFO.:			US 2001-269800P	P 20010220
OTHER SOURCE(S):		MARPAT 137:185506		
GI				



AB A method for treatment of disorders responsive to opening of KDNQ channels comprises administration of title compds. (I; R1 = H, halo, alkyl, Ph, phenylalkyl, heterocyclyl, heterocyclylmethyl, cyano, NR2, etc.; R2 = H, alkyl, cycloalkyl, Ph, phenylalkyl, heterocyclyl, NR2, SR, etc.; R3 = H,

halo, alkyl; R4 = H, Me, PhCH2; R5 = H, alkyl, cycloalkyl, Ph, phenylalkyl, heterocyclyl, heterocyclylmethyl; R = alkyl, alkynyl, Ph, phenylalkyl, heterocyclyl, heterocyclylmethyl). Thus, 4-cyclohexyl-2-(morpholin-4-yl)pyrimidine-5-carboxylic acid (prepn. given) in CH2Cl2 was treated with polymer-supported 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide 4-fluorobenzylamine followed by stirring for 16 h to give 4-cyclohexyl-2-(morpholin-4-yl)pyrimidine-5-carboxylic acid 4-fluorophenylmethylamide. The latter at 20 .mu.M gave a >200% increase in KCNQ2 current in oocytes.

IT 452096-56-9P 452096-58-1P 452096-60-5P  
452096-62-7P 452096-64-9P 452096-66-1P  
452096-68-3P 452096-70-7P 452096-72-9P  
452096-74-1P 452096-76-3P 452096-78-5P  
452096-80-9P 452096-82-1P 452096-84-3P  
452096-86-5P 452096-88-7P 452096-90-1P  
452096-91-2P 452096-92-3P 452096-93-4P  
452096-94-5P 452096-95-6P 452096-96-7P  
452096-97-8P 452096-98-9P 452096-99-0P  
452097-00-6P 452097-01-7P 452097-02-8P  
452097-03-9P 452097-04-0P 452097-05-1P  
452097-06-2P 452097-07-3P 452097-08-4P  
452097-09-5P 452097-10-8P 452097-11-9P  
452097-12-0P 452097-13-1P 452097-14-2P  
452097-15-3P 452097-16-4P 452097-17-5P  
452097-18-6P 452097-19-7P 452097-20-0P  
452097-21-1P 452097-22-2P 452097-23-3P  
452097-24-4P 452097-25-5P 452097-26-6P  
452097-27-7P 452097-28-8P 452097-29-9P  
452097-30-2P 452097-31-3P 452097-32-4P  
452097-33-5P 452097-34-6P 452097-36-8P  
452097-38-0P 452097-39-1P 452097-40-4P  
452097-41-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 2,4-disubstituted pyrimidine-5-carboxamides as KCNQ **potassium channel** modulators)


RN 452096-56-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-cyclohexyl-N-[(4-fluorophenyl)methyl]-2-(4-morpholinyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 452096-55-8

CMF C22 H27 F N4 O2




CM 2

CRN 76-05-1

CMF C2 H F3 O2






RN 452096-58-1 CAPLUS  
CN 5-Pyrimidinecarboxamide, 4-cyclohexyl-2-(4-morpholinyl)-N-(phenylmethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 452096-57-0  
CMF C22 H28 N4 O2



CM 2


CRN 76-05-1  
CMF C2 H F3 O2




RN 452096-60-5 CAPLUS  
CN 5-Pyrimidinecarboxamide, 4-cyclohexyl-N-[(4-fluorophenyl)methyl]-2-(1-piperidinyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 452096-59-2  
CMF C23 H29 F N4 O




CM 2

CRN 76-05-1  
CMF C2 H F3 O2RN 452096-62-7 CAPLUS  
CN 5-Pyrimidinecarboxamide, 4-cyclohexyl-N-[(4-fluorophenyl)methyl]-2-(1-pyrrolidinyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 452096-61-6  
CMF C22 H27 F N4 O

CM 2

CRN 76-05-1  
CMF C2 H F3 O2RN 452096-64-9 CAPLUS  
CN 5-Pyrimidinecarboxamide, 4-cyclohexyl-N-(cyclohexylmethyl)-2-[ethyl(phenylmethyl)amino]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 452096-63-8  
CMF C27 H38 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 452096-66-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-cyclohexyl-2-[ethyl(phenylmethyl)amino]-N-(phenylmethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 452096-65-0


CMF C27 H32 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 452096-68-3 CAPLUS  
CN 5-Pyrimidinecarboxamide, 4-cyclohexyl-2-[ethyl(phenylmethyl)amino]-N-[(4-fluorophenyl)methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 452096-67-2


CMF C27 H31 F N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 452096-70-7 CAPLUS  
CN 5-Pyrimidinecarboxamide, 4-cyclohexyl-N-(cyclohexylmethyl)-2-(2-methyl-1-piperidiny)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 452096-69-4


CMF C24 H38 N4 O



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 452096-72-9 CAPLUS  
CN 5-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-4-propyl-2-(1-pyrrolidinyl)-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 452096-71-8  
CMF C19 H23 F N4 O



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 452096-74-1 CAPLUS  
CN 5-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-2-(1-piperidinyl)-4-propyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 452096-73-0  
CMF C20 H25 F N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 452096-76-3 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-4-(1-methylethyl)-2-(1-pyrrolidinyl)-; trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 452096-75-2


CMF C19 H23 F N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 452096-78-5 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-4-(1-methylethyl)-2-(1-piperidinyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 452096-77-4


CMF C20 H25 F N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 452096-80-9 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-4-(1-methylethyl)-2-(4-morpholinyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 452096-79-6


CMF C19 H23 F N4 O2



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 452096-82-1 CAPLUS  
CN 5-Pyrimidinecarboxamide, 2-[ethyl(phenylmethyl)amino]-4-(1-methylethyl)-N-(phenylmethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 452096-81-0  
CMF C24 H28 N4 O



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 452096-84-3 CAPLUS  
CN 5-Pyrimidinecarboxamide, 4-(2-fluorophenyl)-2-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 452096-83-2  
CMF C23 H20 F4 N4 O






CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 452096-86-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(2-fluorophenyl)-2-(4-morpholinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 452096-85-4


CMF C23 H20 F4 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 452096-88-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-fluorophenyl)-2-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 452096-87-6


CMF C23 H20 F4 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 452096-90-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(2-fluorophenyl)-2-(4-morpholinyl)-N-[[3-(trifluoromethyl)phenyl]methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 452096-89-8


CMF C23 H20 F4 N4 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 452096-91-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-(1-pyrrolidinyl)-4-(trifluoromethyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 452096-92-3 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-(1-pyrrolidinyl)-4-(trifluoromethyl)-N-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 452096-93-4 CAPLUS


CN 5-Pyrimidinecarboxamide, N-[(4-chlorophenyl)methyl]-2-(1-pyrrolidinyl)-4-

(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 452096-94-5 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[(4-chlorophenyl)methyl]-2-(4-morpholinyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 452096-95-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-(hexahydro-1H-azepin-1-yl)-N-[(4-methylphenyl)methyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 452096-96-7 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-(1-pyrrolidinyl)-N-[[4-(trifluoromethoxy)phenyl]methyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 452096-97-8 CAPLUS  
 CN 5-Pyrimidinecarboxamide, 2-(4-morpholinyl)-N-[[4-(trifluoromethoxy)phenyl]methyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 452096-98-9 CAPLUS  
 CN 5-Pyrimidinecarboxamide, 2-(1-piperidinyl)-N-[[4-(trifluoromethoxy)phenyl]methyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 452096-99-0 CAPLUS  
 CN 5-Pyrimidinecarboxamide, 2-(diethylamino)-N-[[4-(trifluoromethoxy)phenyl]methyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 452097-00-6 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[(4-bromophenyl)methyl]-2-(1-pyrrolidinyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 452097-01-7 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[[4-(dimethylamino)phenyl]methyl]-2-(1-pyrrolidinyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 452097-02-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-(4-morpholinyl)-4-(trifluoromethyl)-N-[[4-(trifluoromethyl)thio]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-03-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-amino-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-04-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(1-ethylpropyl)amino]-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-05-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[ethyl(2-hydroxyethyl)amino]-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-06-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-(methylpentylamino)-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-07-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2,4-di-1-pyrrolidinyl-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-08-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-(cyclopentylamino)-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 452097-09-5 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[(phenylmethyl)amino]-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 452097-10-8 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[methyl(phenylmethyl)amino]-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)






RN 452097-11-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(4-chlorophenyl)methylamino]-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-12-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-(methyl-2-propynylamino)-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 452097-13-1 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-(diethylamino)-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 452097-14-2 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[methyl[4-(trifluoromethoxy)phenyl]amino]-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-15-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[methyl(4-nitrophenyl)amino]-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-16-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-(2-propynylamino)-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 452097-17-5 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)methylamino]-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 452097-18-6 CAPLUS


CN 5-Pyrimidinecarboxamide, 2-[(3,4-dichlorophenyl)methylamino]-4-(1-

pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-19-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-(4-fluorophenoxy)-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-20-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-(2-methoxyphenoxy)-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-21-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-(2-propynyloxy)-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-22-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(1-pyrrolidinyl)-2-(2-thienylmethoxy)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-23-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[2-(4-fluorophenyl)ethoxy]-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-24-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-(3,4-dimethoxyphenyl)-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-25-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-(2-methoxyphenyl)-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-26-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(1-pyrrolidinyl)-2-(3-thienyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-27-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(1-pyrrolidinyl)-2-(2-thienyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-28-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-chlorophenyl)methyl]thio]-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-29-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(2-furanylmethyl)thio]-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-30-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(4-nitrophenyl)thio]-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-31-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[[[3-methylphenyl)methyl]thio]-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-32-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(2-chlorophenyl)thio]-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-33-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-(cyclopropylthio)-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-34-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(1-pyrrolidinyl)-2-(2-thienylthio)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-36-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(2-methylpropyl)thio]-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-38-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-[(phenylmethyl)thio]-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-39-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-(diethylamino)-N-[(5-methyl-2-furanyl)methyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 452097-40-4 CAPLUS


CN 5-Pyrimidinecarboxamide, N-(2-furanylmethyl)-2-(1-pyrrolidinyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 452097-41-5 CAPLUS  
CN 5-Pyrimidinecarboxamide, N-[(5-methyl-2-furanyl)methyl]-2-(4-morpholinyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



IT **452097-47-1P 452097-48-2P**  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of 2,4-disubstituted pyrimidine-5-carboxamides as KCNQ  
**potassium channel** modulators)  
RN 452097-47-1 CAPLUS  
CN 5-Pyrimidinecarboxamide, 2,4-dichloro-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 452097-48-2 CAPLUS  
CN 5-Pyrimidinecarboxamide, 2-chloro-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:220565 CAPLUS

DOCUMENT NUMBER: 136:247604

TITLE: Preparation of pyrimidine and pyridine derivatives as  
N-type calcium channel inhibitors and analgesics


Searched by Barb O'Bryen, STIC 308-4291



INVENTOR(S): Ohno, Seiji; Otani, Kayo; Niwa, Seiji; Iwayama, Satoshi; Takahara, Akira; Koganei, Hajime; Ono, Yukitsugu; Fujita, Shinichi; Takeda, Tomoko; Hagiwara, Masako; Okajima, Akiko  
PATENT ASSIGNEE(S): Ajinomoto Co., Inc., Japan  
SOURCE: PCT Int. Appl., 207 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022588	A1	20020321	WO 2001-JP7841	20010910
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001084504	A5	20020326	AU 2001-84504	20010910
PRIORITY APPLN. INFO.:			JP 2000-280438	A 20000914
			JP 2001-126832	A 20010425
			WO 2001-JP7841	W 20010910


OTHER SOURCE(S): MARPAT 136:247604  
GI



AB The title compds., e.g. I [A = 1-naphthyl, pyridin-3-yl, etc.; C = alkyl, etc.; E = alkyl, etc.; F = thiophen-3-yl, etc.; X1 = NR14, etc.; R14 = H, etc.; Y = (un)satd. hydrocarbon moiety, etc.], are prepd. I are useful as therapeutic agents for pain and for various diseases in which N-type calcium channels participate. In rats dosed orally with 4-(2,4-dimethylphenyl)-6-methyl-2-(methylthio)-N-(3-phenylpropyl)-5-pyrimidinecarboxamide at 3 mg/kg, the flinching behavior frequency was 39.+-11 times/60 min vs. 116.+-8 times/60 min in controls.


IT 404568-26-9P 404568-29-2P 404568-30-5P 404569-12-6P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(prepn. of pyrimidine and pyridine derivs. as N-type calcium channel inhibitors and analgesics)

RN 404568-26-9 CAPLUS  
CN 5-Pyrimidinecarboxamide, 4-(3,4-dichlorophenyl)-6-methyl-2-(methylthio)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404568-29-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,5-dichlorophenyl)-6-methyl-2-(methylthio)-N-(3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)




RN 404568-30-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,4-dichlorophenyl)-6-methyl-2-(methylthio)-N-(3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)



RN 404569-12-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(2,4-dimethylphenyl)-6-methyl-2-(methylthio)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




IT 404568-20-3P 404568-21-4P 404568-22-5P  
404568-23-6P 404568-24-7P 404568-25-8P  
404568-27-0P 404568-28-1P 404568-31-6P  
404568-32-7P 404568-33-8P 404568-34-9P  
404568-35-0P 404568-36-1P 404568-37-2P  
404568-38-3P 404568-39-4P 404568-40-7P  
404568-41-8P 404568-42-9P 404568-43-0P  
404568-44-1P 404568-45-2P 404568-46-3P  
404568-47-4P 404568-48-5P 404568-49-6P  
404568-50-9P 404568-51-0P 404568-52-1P  
404568-53-2P 404568-54-3P 404568-55-4P  
404568-56-5P 404568-57-6P 404568-58-7P  
404568-59-8P 404568-60-1P 404568-61-2P  
404568-62-3P 404568-63-4P 404568-64-5P  
404568-65-6P 404568-66-7P 404568-67-8P  
404568-68-9P 404568-69-0P 404568-70-3P  
404568-71-4P 404568-72-5P 404568-73-6P  
404568-74-7P 404568-75-8P 404568-76-9P  
404568-77-0P 404568-78-1P 404568-79-2P  
404568-80-5P 404568-81-6P 404568-82-7P  
404568-83-8P 404568-84-9P 404568-85-0P  
404568-86-1P 404568-87-2P 404568-88-3P  
404568-89-4P 404568-90-7P 404568-91-8P  
404568-92-9P 404568-93-0P 404568-94-1P  
404568-95-2P 404568-96-3P 404568-97-4P  
404568-98-5P 404568-99-6P 404569-00-2P  
404569-01-3P 404569-02-4P 404569-03-5P  
404569-04-6P 404569-05-7P 404569-06-8P  
404569-07-9P 404569-08-0P 404569-09-1P  
404569-10-4P 404569-11-5P 404569-13-7P  
404569-14-8P 404569-15-9P 404569-16-0P  
404569-17-1P 404569-18-2P 404569-19-3P  
404569-20-6P 404569-21-7P 404569-22-8P  
404569-23-9P 404569-24-0P 404569-25-1P  
404569-26-2P 404569-27-3P 404569-28-4P  
404569-29-5P 404569-30-8P 404569-31-9P  
404569-32-0P 404569-33-1P 404569-34-2P  
404569-35-3P 404569-36-4P 404569-37-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(prepn. of pyrimidine and pyridine derivs. as N-type calcium channel  
inhibitors and analgesics)

RN 404568-20-3 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-(3-chlorophenyl)-6-methyl-2-(methylthio)-N-(3-  
phenyl-2-propenyl)- (9CI) (CA INDEX NAME)



RN 404568-21-4 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-(3-chlorophenyl)-N-(3,3-diphenylpropyl)-6-

methyl-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 404568-22-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3-chlorophenyl)-6-methyl-N-(3-phenyl-2-propenyl)-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 404568-23-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3-chlorophenyl)-6-methyl-2-phenyl-N-(3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)




RN 404568-24-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3-chlorophenyl)-N-(3,3-diphenylpropyl)-6-methyl-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 404568-25-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,4-dichlorophenyl)-N-(3,3-diphenylpropyl)-6-methyl-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 404568-27-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,5-dichlorophenyl)-N-(3,3-diphenylpropyl)-6-methyl-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 404568-28-1 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-(3,5-dichlorophenyl)-6-methyl-2-(methylthio)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404568-31-6 CAPLUS  
CN 5-Pyrimidinecarboxamide, 4-(3,5-dichlorophenyl)-2,6-dimethyl-N-(3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)



RN 404568-32-7 CAPLUS  
CN 5-Pyrimidinecarboxamide, 4-(3-chlorophenyl)-6-methyl-2-phenyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404568-33-8 CAPLUS  
CN 5-Pyrimidinecarboxamide, 4-(3-chlorophenyl)-6-methyl-N-(3-phenylpropyl)-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 404568-34-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3-chlorophenyl)-2,6-dimethyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404568-35-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3-chlorophenyl)-6-methyl-2-(methylthio)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404568-36-1 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-(3-chlorophenyl)-2,6-dimethyl-N-(3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)



RN 404568-37-2 CAPLUS  
CN 5-Pyrimidinecarboxamide, 4-(3,4-dichlorophenyl)-2,6-dimethyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404568-38-3 CAPLUS  
CN 5-Pyrimidinecarboxamide, 4-(3,4-dichlorophenyl)-6-methyl-N-(3-phenylpropyl)-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 404568-39-4 CAPLUS  
CN 5-Pyrimidinecarboxamide, 4-(3,5-dichlorophenyl)-6-methyl-2-phenyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)






RN 404568-40-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,5-dichlorophenyl)-6-methyl-N-(3-phenylpropyl)-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 404568-41-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,5-dichlorophenyl)-2,6-dimethyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404568-42-9 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-(3,4-dichlorophenyl)-6-methyl-2-phenyl-N-(4-phenylbutyl)- (9CI) (CA INDEX NAME)




RN 404568-43-0 CAPLUS  
CN 5-Pyrimidinecarboxamide, 4-(3,4-dichlorophenyl)-6-methyl-N-(4-phenylbutyl)-  
2-(3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 404568-44-1 CAPLUS  
CN 5-Pyrimidinecarboxamide, 4-(3,4-dichlorophenyl)-2,6-dimethyl-N-(4-  
phenylbutyl)- (9CI) (CA INDEX NAME)




RN 404568-45-2 CAPLUS  
CN 5-Pyrimidinecarboxamide, 4-(3,4-dichlorophenyl)-6-methyl-2-(methylthio)-N-  
(4-phenylbutyl)- (9CI) (CA INDEX NAME)




RN 404568-46-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,4-dichlorophenyl)-6-methyl-2-phenyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 404568-47-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,4-dichlorophenyl)-6-methyl-N-(2-phenylethyl)-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 404568-48-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,4-dichlorophenyl)-2,6-dimethyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 404568-49-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,4-dichlorophenyl)-6-methyl-2-(methylthio)-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)




RN 404568-50-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,4-dichlorophenyl)-N-(3,3-diphenylpropyl)-2,6-dimethyl- (9CI) (CA INDEX NAME)




RN 404568-51-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,5-dichlorophenyl)-N-(3,3-diphenylpropyl)-2,6-dimethyl- (9CI) (CA INDEX NAME)




RN 404568-52-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,4-dichlorophenyl)-6-methyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404568-53-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,4-dichlorophenyl)-2,6-dimethyl-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 404568-54-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,4-dichlorophenyl)-6-methyl-2-(methylthio)-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 404568-55-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-methoxyphenyl)-6-methyl-2-phenyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404568-56-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-methoxyphenyl)-6-methyl-N-(3-phenylpropyl)-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 404568-57-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-methyl-N-(3-phenylpropyl)-2,6-di-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 404568-58-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 2,4-dimethyl-N-(3-phenylpropyl)-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 404568-59-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,4-dichlorophenyl)-6-methyl-2-(methylsulfonyl)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404568-60-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-methyl-2-phenyl-N-(3-phenylpropyl)-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 404568-61-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-methyl-2-(methylthio)-N-(3-phenylpropyl)-6-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 404568-62-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2-amino-4-(3,4-dichlorophenyl)-6-methyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404568-63-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-methoxyphenyl)-6-methyl-2-(methylthio)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404568-64-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-methyl-6-(3-nitrophenyl)-2-phenyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)







RN 404568-65-6 CAPLUS  
CN 5-Pyrimidinecarboxamide, 4-methyl-6-(3-nitrophenyl)-N-(3-phenylpropyl)-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 404568-66-7 CAPLUS  
CN 5-Pyrimidinecarboxamide, 2,4-dimethyl-6-(3-nitrophenyl)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 404568-67-8 CAPLUS  
CN 5-Pyrimidinecarboxamide, 4-methyl-2-(methylthio)-6-(3-nitrophenyl)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404568-68-9 CAPLUS  
CN 5-Pyrimidinecarboxamide, 4-methyl-6-(3-methylphenyl)-2-phenyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404568-69-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-methyl-6-(3-methylphenyl)-N-(3-phenylpropyl)-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 404568-70-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 2,4-dimethyl-6-(3-methylphenyl)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404568-71-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-methyl-6-(3-methylphenyl)-2-(methylthio)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404568-72-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3-fluorophenyl)-6-methyl-2-phenyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404568-73-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3-fluorophenyl)-6-methyl-N-(3-phenylpropyl)-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 404568-74-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3-fluorophenyl)-2,6-dimethyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404568-75-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3-fluorophenyl)-6-methyl-2-(methylthio)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404568-76-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3-methoxyphenyl)-6-methyl-2-(methylthio)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404568-77-0 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-(3-methoxyphenyl)-6-methyl-2-phenyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404568-78-1 CAPLUS  
CN 5-Pyrimidinecarboxamide, 4-(3-methoxyphenyl)-6-methyl-N-(3-phenylpropyl)-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 404568-79-2 CAPLUS  
CN 5-Pyrimidinecarboxamide, 4-(3-methoxyphenyl)-2,6-dimethyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 404568-80-5 CAPLUS  
CN 5-Pyrimidinecarboxamide, 4-(3,5-dichlorophenyl)-2-(1,1-dimethylethyl)-6-methyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404568-81-6 CAPLUS  
CN 5-Pyrimidinecarboxamide, 2-cyclopropyl-4-(3,5-dichlorophenyl)-6-methyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404568-82-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,5-dichlorophenyl)-6-methyl-2-(4-morpholinyl)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404568-83-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,5-dichlorophenyl)-6-methyl-N-(3-phenylpropyl)-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 404568-84-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,5-dichlorophenyl)-6-methyl-N-(3-phenylpropyl)-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 404568-85-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-methyl-2-(methylthio)-6-(2-naphthalenyl)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404568-86-1 CAPLUS

5-Pyrimidinecarboxamide, 4-methyl-6-(4-methylphenyl)-2-phenyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404568-87-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-methyl-6-(4-methylphenyl)-2-(methylthio)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404568-88-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,5-dichlorophenyl)-6-methyl-N-(3-phenylpropyl)-2-(1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)




RN 404568-89-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,5-dichlorophenyl)-6-methyl-2-(methylamino)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 404568-90-7 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-(3,5-dichlorophenyl)-2-(dimethylamino)-6-methyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)






RN 404568-91-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,5-dichlorophenyl)-2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-methyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404568-92-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3-chlorophenyl)-6-methyl-N-(3-phenylpropyl)-2-(1-piperidinyl)- (9CI) (CA INDEX NAME)




RN 404568-93-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,5-dichlorophenyl)-6-methyl-N-(3-phenylpropyl)-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 404568-94-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 2,4-dimethyl-6-[4-(1-methylethyl)phenyl]-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404568-95-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-methyl-6-[4-(1-methylethyl)phenyl]-2-(methylthio)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404568-96-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-[4-(1,1-dimethylethyl)phenyl]-2,6-dimethyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404568-97-4 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-[4-(1,1-dimethylethyl)phenyl]-6-methyl-2-(methylthio)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404568-98-5 CAPLUS  
CN 5-Pyrimidinecarboxamide, 4-(3-chlorophenyl)-6-methyl-2-[(2-methylpropyl)amino]-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404568-99-6 CAPLUS  
CN 5-Pyrimidinecarboxamide, 4-(3-chlorophenyl)-2-methoxy-6-methyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 404569-00-2 CAPLUS  
CN 5-Pyrimidinecarboxamide, 2,4-dimethyl-6-(2-naphthalenyl)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404569-01-3 CAPLUS  
CN 5-Pyrimidinecarboxamide, 2,4-dimethyl-6-(1-naphthalenyl)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404569-02-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-methyl-2-(methylthio)-6-(1-naphthalenyl)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404569-03-5 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,4-dimethylphenyl)-2,6-dimethyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404569-04-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,4-dimethylphenyl)-6-methyl-2-(methylthio)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404569-05-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3-chlorophenyl)-6-methyl-N-(3-phenylpropyl)-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 404569-06-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,5-dichlorophenyl)-6-methyl-N-(3-phenylpropyl)-2-(2-thienyl)- (9CI) (CA INDEX NAME)




RN 404569-07-9 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-(3-chlorophenyl)-6-methyl-N-(3-phenylpropyl)-2-[2-(1-piperidinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 404569-08-0 CAPLUS  
CN 5-Pyrimidinecarboxamide, 4-(3,4-dichlorophenyl)-2-methoxy-6-methyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404569-09-1 CAPLUS  
CN 5-Pyrimidinecarboxamide, 4-(3-chloro-4-methoxyphenyl)-2-cyclopropyl-6-methyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 404569-10-4 CAPLUS  
CN 5-Pyrimidinecarboxamide, 4-(3-chloro-4-methoxyphenyl)-6-methyl-2-(methylthio)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404569-11-5 CAPLUS  
CN 5-Pyrimidinecarboxamide, 2-cyclopropyl-4-(2,4-dimethylphenyl)-6-methyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404569-13-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(2-chlorophenyl)-6-methyl-2-(methylthio)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404569-14-8 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,5-dichloro-4-methoxyphenyl)-6-methyl-2-(methylthio)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404569-15-9 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,5-dichlorophenyl)-6-methyl-2-phenoxy-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404569-16-0 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-methyl-6-(2-methylphenyl)-2-(methylthio)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404569-17-1 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-methoxy-3-methylphenyl)-6-methyl-2-(methylthio)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 404569-18-2 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-(3,5-dichlorophenyl)-6-methyl-2-(1-methylethyl)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 404569-19-3 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-(3,5-dichlorophenyl)-6-methyl-2-(2-methyl-4-thiazolyl)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)






RN 404569-20-6 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,5-dichlorophenyl)-6-methyl-2-(phenoxymethyl)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404569-21-7 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,5-dichlorophenyl)-2-ethoxy-6-methyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404569-22-8 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-(3,5-dichlorophenyl)-2-ethyl-6-methyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404569-23-9 CAPLUS  
CN 5-Pyrimidinecarboxamide, 4-(3,5-dichlorophenyl)-6-methyl-N-(3-phenylpropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 404569-24-0 CAPLUS  
CN 5-Pyrimidinecarboxamide, 2-butyl-4-(3,5-dichlorophenyl)-6-methyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RN 404569-25-1 CAPLUS  
CN 5-Pyrimidinecarboxamide, 4-(2,4-dimethylphenyl)-6-methyl-2-(methylsulfinyl)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404569-26-2 CAPLUS  
CN 5-Pyrimidinecarboxamide, 4-(2,4-dimethylphenyl)-6-methyl-N-(3-phenylpropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 404569-27-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(3,5-dichlorophenyl)-6-ethyl-2-(methylthio)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404569-28-4 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(2,4-dichlorophenyl)-6-methyl-2-(methylthio)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404569-29-5 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-(2,6-dichlorophenyl)-6-methyl-2-(methylthio)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404569-30-8 CAPLUS  
CN 5-Pyrimidinecarboxamide, 4-(2,4-dimethylphenyl)-6-methyl-2-(methylthio)-N-(3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)




RN 404569-31-9 CAPLUS  
CN 5-Pyrimidinecarboxamide, 4-(2,4-dichlorophenyl)-6-methyl-N-(3-phenylpropyl)-2-propyl- (9CI) (CA INDEX NAME)



RN 404569-32-0 CAPLUS  
CN 5-Pyrimidinecarboxamide, 4-(2,5-dimethylphenyl)-6-methyl-2-(methylthio)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404569-33-1 CAPLUS  
CN 5-Pyrimidinecarboxamide, 4-(2,5-dimethylphenyl)-6-methyl-N-(3-phenylpropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 404569-34-2 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-chlorophenyl)-6-methyl-2-(methylthio)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404569-35-3 CAPLUS

CN 5-Pyrimidinecarboxamide, 4-(4-chlorophenyl)-6-methyl-N-(3-phenylpropyl)-2-propyl- (9CI) (CA INDEX NAME)




RN 404569-36-4 CAPLUS


CN 5-Pyrimidinecarboxamide, 4-(2,6-dimethylphenyl)-6-methyl-2-(methylthio)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)




RN 404569-37-5 CAPLUS  
 CN 5-Pyrimidinecarboxamide, 4-(2,6-dimethylphenyl)-6-methyl-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



IT **404570-13-4**  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (prepn. of pyrimidine and pyridine derivs. as N-type calcium channel inhibitors and analgesics).  
 RN 404570-13-4 CAPLUS  
 CN 5-Pyrimidinecarboxamide, 4-(3-chlorophenyl)-6-methyl-2-(methylsulfonyl)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



IT **404569-74-0P**  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (prepn. of pyrimidine and pyridine derivs. as N-type calcium channel inhibitors and analgesics).  
 RN 404569-74-0 CAPLUS  
 CN 5-Pyrimidinecarboxamide, 4-(3,5-dichlorophenyl)-6-methyl-2-(methylsulfonyl)-N-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L41 ANSWER 7 OF 18 USPATFULL

ACCESSION NUMBER: 2003:79133 USPATFULL

TITLE: ~~Imidazo-triazine derivatives as ligands for GABA~~  
receptors

INVENTOR(S): Carling, William Robert, Bishops Stortford, UNITED KINGDOM  
Hallett, David James, Watford, UNITED KINGDOM  
Russell, Michael Geoffrey Neil, Welwyn Garden City, UNITED KINGDOM  
Street, Leslie Joseph, Little Hallingbury, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003055060	A1	20030320
APPLICATION INFO.:	US 2002-195274	A1	20020715 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2001-17277	20010716
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MERCK AND CO INC, P.O BOX 2000, RAHWAY, NJ, 070650907	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1172	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A class of 7-phenylimidazo[1,2-b][1,2,4]triazine derivatives, substituted at the meta position of the phenyl ring by a (cyano)(fluoro)phenyl moiety, being selective ligands for GABA.sub.A receptors, in particular having good affinity for the .alpha.2 and/or .alpha.3 subunit thereof, are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety and convulsions.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 425379-62-0P 425379-63-1P


(prepn. of imidazo-triazines as ligands for GABA receptors)

RN 425379-62-0 USPATFULL

CN Boronic acid, [3-[5-(aminocarbonyl)-4-pyrimidinyl]-4-fluorophenyl]- (9CI)  
(CA INDEX NAME)



RN 425379-63-1 USPATFULL  
CN 5-Pyrimidinecarboxamide, 4-[2-fluoro-5-[3-(1-hydroxy-1-methylethyl)imidazo[1,2-b][1,2,4]triazin-7-yl]phenyl]- (9CI) (CA INDEX NAME)



L41 ANSWER 8 OF 18 USPATFULL

ACCESSION NUMBER: 2003:45335 USPATFULL

TITLE: Aromatic nitrogen-containing 6-membered cyclic compounds

INVENTOR(S): Yamada, Koichiro, Saitama-ken, JAPAN  
Matsuki, Kenji, Saitama-ken, JAPAN  
Omori, Kenji, Saitama-shi, JAPAN  
Kikkawa, Kohei, Kawaguchi-shi, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003032647	A1	20030213
APPLICATION INFO.:	US 2001-925892	A1	20010810 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2000-JP6258, filed on 13 Sep 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1999-261852	19990916
	JP 2000-130371	20000428
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Finnegan, Henderson, Farabow,, Garrett & Dunner, L.L.P., 1300 I Street, N.W., Washington, DC, 20005-3315	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2279	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An aromatic nitrogen-containing 6-membered cyclic compound of the formula (I): ##STR1##

wherein Ring A is a substituted or unsubstituted nitrogen-containing heterocyclic group; R.sup.1 is a substituted or unsubstituted lower



alkyl group, --NH--Q--R<sup>sup.3</sup> (R<sup>sup.3</sup> is a substituted or unsubstituted nitrogen containing heterocyclic group, and Q is a lower alkylene group or a single bond), or --NH--R<sup>sup.4</sup> (R<sup>sup.4</sup> is a substituted or unsubstituted cycloalkyl group); R<sup>sup.2</sup> is a substituted or unsubstituted aryl group; one of Y and Z is .dbd.CH--, and the other is .dbd.N--, or a pharmaceutically acceptable salt thereof, these compounds exhibiting excellent selective PDE V inhibitory activities, and hence, being useful in the prophylaxis or treatment of penile erectile dysfunction, etc.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 330786-26-0P 330786-28-2P 330786-37-3P

(prepn. and effect of heteroarom. compds. as PDE V activity inhibitors)

RN 330786-26-0 USPATFULL

CN 5-Pyrimidinecarboxamide, 2-[2-(hydroxymethyl)-1-pyrrolidinyl]-4-(phenylthio)-N-(2-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)




*h*

RN 330786-28-2 USPATFULL


CN 5-Pyrimidinecarboxamide, 4-[[[(3-chlorophenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-(2-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330786-37-3 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(methylthio)-N-5-pyrimidinyl]- (9CI) (CA INDEX NAME)




IT 330784-22-0P 330784-25-3P 330784-26-4P  
330784-27-5P 330784-28-6P 330784-29-7P  
330784-30-0P 330784-31-1P 330784-32-2P  
330784-33-3P 330784-34-4P 330784-35-5P  
330784-36-6P 330784-37-7P 330784-38-8P  
330784-39-9P 330784-40-2P 330784-41-3P  
330784-42-4P 330784-47-9P 330784-48-0P  
330784-49-1P 330784-50-4P 330784-52-6P  
330784-53-7P 330784-54-8P 330784-55-9P  
330784-56-0P 330784-57-1P 330784-58-2P  
330784-59-3P 330784-60-6P 330784-61-7P  
330784-62-8P 330784-63-9P 330784-64-0P  
330784-65-1P 330784-67-3P 330784-68-4P  
330784-69-5P 330784-70-8P 330784-71-9P  
330784-72-0P 330784-73-1P 330784-74-2P  
330784-75-3P 330784-76-4P 330784-77-5P  
330784-78-6P 330784-79-7P 330784-81-1P  
330784-82-2P 330784-83-3P 330784-84-4P  
330784-85-5P 330784-86-6P 330784-87-7P  
330784-88-8P 330784-89-9P 330784-90-2P  
330784-91-3P 330784-92-4P 330784-93-5P  
330784-94-6P 330784-95-7P 330784-96-8P  
330784-97-9P 330784-98-0P 330784-99-1P  
330785-00-7P 330785-01-8P 330785-02-9P  
330785-03-0P 330785-04-1P 330785-05-2P  
330785-06-3P 330785-07-4P 330785-13-2P  
330785-14-3P 330785-15-4P 330785-16-5P  
330785-17-6P 330785-18-7P 330785-19-8P  
330785-20-1P 330785-21-2P 330785-22-3P  
330785-23-4P 330785-24-5P 330785-25-6P  
330785-26-7P 330785-27-8P 330785-28-9P  
330785-29-0P 330785-30-3P 330785-31-4P  
330785-32-5P 330785-33-6P 330785-34-7P  
330785-35-8P 330785-36-9P 330785-37-0P  
330785-38-1P 330785-39-2P 330785-40-5P  
330785-41-6P 330785-42-7P 330785-43-8P  
330785-44-9P 330785-45-0P 330785-46-1P  
330785-47-2P 330785-48-3P 330785-49-4P  
330785-50-7P 330785-51-8P 330785-52-9P  
330785-53-0P 330785-54-1P 330785-55-2P  
330785-56-3P 330785-57-4P 330785-58-5P  
330785-59-6P 330785-65-4P 330785-66-5P  
330785-67-6P 330785-68-7P 330785-69-8P  
330785-70-1P 330785-71-2P 330785-72-3P  
330785-73-4P 330785-75-6P 330785-76-7P  
330785-77-8P 330785-79-0P

(prepn. and effect of heteroarom. compds. as PDE V activity inhibitors)

RN 330784-22-0 USPATFULL


CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-  
[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-(2-pyridinylmethyl)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 330784-25-3 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-N-[(4-methyl-2-morpholinyl)methyl]- (9CI) (CA INDEX NAME)



RN 330784-26-4 USPATFULL


CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-N-(2-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)



RN 330784-27-5 USPATFULL


CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-N-(trans-4-hydroxycyclohexyl)-(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 330784-28-6 USPATFULL


CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(5,8-dihydro-1,7-naphthyridin-7(6H)-yl)-N-[2-(4-morpholinyl)ethyl]-(9CI) (CA INDEX NAME)



RN 330784-29-7 USPATFULL


CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-N-(trans-4-methoxycyclohexyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 330784-30-0 USPATFULL


CN 5-Pyrimidinecarboxamide, 4-[[[(3-cyano-4-methoxyphenyl)methyl]amino]-2-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-N-(2-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)



RN 330784-31-1 USPATFULL


CN 5-Pyrimidinecarboxamide, 4-[[[(3-cyano-4-methoxyphenyl)methyl]amino]-2-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-N-(trans-4-hydroxycyclohexyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 330784-32-2 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-cyano-4-methoxyphenyl)methyl]amino]-2-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-N-[2-(4-morpholinyl)ethyl]- (9CI)  
(CA INDEX NAME)



RN 330784-33-3 USPATFULL


CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 330784-34-4 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-  
[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-(2-pyridinylmethyl)-,  
monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 330784-35-5 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-  
[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-(5-pyrimidinylmethyl)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 330784-36-6 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-  
[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-[2-(4-morpholinyl)ethyl]-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330784-37-7 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-N-(trans-4-hydroxycyclohexyl)-2-(4-methyl-3-oxo-1-piperazinyl)]- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 330784-38-8 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-(4-pyridazinylmethyl)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 330784-39-9 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-(4-pyrimidinylmethyl)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 330784-40-2 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-[(4-methyl-2-morpholinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330784-41-3 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(4-formyl-1-piperazinyl)-N-(trans-4-hydroxycyclohexyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 330784-42-4 USPATFULL

CN 5-Pyrimidinecarboxamide, 2-[(2S,5R)-2,5-bis(hydroxymethyl)-1-pyrrolidinyl]-4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-N-(2-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330784-47-9 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-(2-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 330784-48-0 USPATFULL  
CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-  
[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-(2-pyrimidinylmethyl)-,  
dibzenesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 330784-47-9

CMF C23 H26 Cl N7 O3


Absolute stereochemistry.



CM 2


CRN 98-11-3

CMF C6 H6 O3 S



RN 330784-49-1 USPATFULL  
CN 5-Pyrimidinecarboxamide, 2-[[[(3-chloro-4-methoxyphenyl)methyl][(2S)-2-(  
hydroxymethyl)-1-pyrrolidinyl]amino]-N-(1,3,5-trimethyl-1H-pyrazol-4-  
yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330784-50-4 USPATFULL


CN 5-Pyrimidinecarboxamide, 2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-4-[[[4-methoxyphenyl)methyl]amino]-N-(2-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 330784-52-6 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(3,4-dihydro-2(1H)-isoquinolinyl)-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 330784-53-7 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(5,8-dihydro-1,7-naphthyridin-7(6H)-yl)-N-(2-pyrimidinylmethyl)- (9CI)  
(CA INDEX NAME)




RN 330784-54-8 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-N-(2-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)



RN 330784-55-9 USPATFULL


CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(5,8-dihydro-1,7-naphthyridin-7(6H)-yl)-N-[(4-methyl-2-morpholinyl)methyl]- (9CI) (CA INDEX NAME)



RN 330784-56-0 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 330784-57-1 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-4-[[[3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330784-58-2 USPATFULL


CN 5-Pyrimidinecarboxamide, 4-[[[3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-(trans-4-methoxycyclohexyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 330784-59-3 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 330784-60-6 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-N-[(4-methyl-2-morpholinyl)methyl]- (9CI) (CA INDEX NAME)




RN 330784-61-7 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-N-(trans-4-hydroxycyclohexyl)-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)



(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330784-62-8 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-N-(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330784-63-9 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(1,2,3,4,6,7-hexahydro-3-oxo-5H-pyrazolo[4,3-c]pyridin-5-yl)-N-(trans-4-hydroxycyclohexyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 330784-64-0 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-[3-(1H-imidazol-1-yl)propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330784-65-1 USPATFULL


CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-N-[[4-(dimethylamino)-2-pyrimidinyl]methyl]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330784-67-3 USPATFULL


CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[4-(hydroxymethyl)-1H-imidazol-1-yl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 330784-68-4 USPATFULL


CN 5-Pyrimidinecarboxamide, 2-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-N-(trans-4-hydroxycyclohexyl)-4-[[ (4-methoxy-3-nitrophenyl)methyl]amino]-(9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 330784-69-5 USPATFULL


CN 5-Pyrimidinecarboxamide, 2-(5,6-dihydroimidazo[1,2-a]pyrazin-7(8H)-yl)-4-[[ (4-methoxy-3-nitrophenyl)methyl]amino]-N-[2-(4-morpholinyl)ethyl]-(9CI) (CA INDEX NAME)



RN 330784-70-8 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[ (3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-[2-(3-oxo-1-piperazinyl)ethyl]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330784-71-9 USPATFULL


CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-[2-(4-methyl-3-oxo-1-piperazinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 330784-72-0 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(1-piperidiny)]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 330784-73-1 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(4-methyl-3-oxo-1-piperazinyl)-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 330784-74-2 USPATFULL


CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[3,4-dihydro-3-(hydroxymethyl)-2(1H)-isoquinolinyl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 330784-75-3 USPATFULL


CN 5-Pyrimidinecarboxamide, 2-[(2R,5S)-2,5-bis(hydroxymethyl)-1-pyrrolidinyl]-4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-N-(trans-4-hydroxycyclohexyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 330784-76-4 USPATFULL


CN 5-Pyrimidinecarboxamide, 2-(2-amino-6,7-dihydrothiazolo[5,4-c]pyridin-5(4H)-yl)-4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-N-(2-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 330784-77-5 USPATFULL


CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(1,2,3,4,6,7-hexahydro-3-oxo-5H-pyrazolo[4,3-c]pyridin-5-yl)]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 330784-78-6 USPATFULL


CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-N-(trans-4-hydroxycyclohexyl)-2-[2-(hydroxymethyl)-1H-pyrrol-1-yl]]- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 330784-79-7 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(4-formyl-1-piperazinyl)-N-(2-pyridinylmethyl)-, monohydrochloride (9CI)  
(CA INDEX NAME)




● HCl

RN 330784-81-1 USPATFULL

CN 5-Pyrimidinecarboxamide, N-(trans-4-hydroxycyclohexyl)-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-4-[[[(4-methoxy-3-nitrophenyl)methyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 330784-82-2 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(4-




methyl-3-oxo-1-piperazinyl)-N-(2-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)



RN 330784-83-3 USPATFULL


CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl)-N-(trans-4-hydroxycyclohexyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 330784-84-4 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(1,2,3,4,6,7-hexahydro-3-oxo-5H-pyrazolo[4,3-c]pyridin-5-yl)-N-(2-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)



RN 330784-85-5 USPATFULL


CN 3H-Imidazo[4,5-c]pyridine-6-carboxylic acid, 3-[4-[[3-chloro-4-methoxyphenyl)methyl]amino]-5-[[2-pyridinylmethyl)amino]carbonyl]-2-pyrimidinyl]-4,5,6,7-tetrahydro-, methyl ester (9CI) (CA INDEX NAME)



RN 330784-86-6 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[3-chloro-4-methoxyphenyl)methyl]amino]-N-(trans-4-hydroxycyclohexyl)-2-(3-oxo-1-piperazinyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 330784-87-7 USPATFULL


CN 5-Pyrimidinecarboxamide, 2-[(2R,5R)-2,5-bis(hydroxymethyl)-1-pyrrolidinyl]-4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-N-(trans-4-hydroxycyclohexyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 330784-88-8 USPATFULL


CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(4-morpholinyl)-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 330784-89-9 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-cyano-4-methoxyphenyl)methyl]amino]-2-[3,4-dihydro-3-(hydroxymethyl)-2(1H)-isoquinolinyl]-N-(trans-4-hydroxycyclohexyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 330784-90-2 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-N-(trans-4-hydroxycyclohexyl)-2-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 330784-91-3 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-N-(trans-4-hydroxycyclohexyl)-2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




HCl

RN 330784-92-4 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-N-(trans-4-hydroxycyclohexyl)-2-[2-(hydroxymethyl)-4-morpholinyl]- (9CI)  
(CA INDEX NAME)


Relative stereochemistry.



RN 330784-93-5 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-cyano-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(methoxymethyl)-1-pyrrolidinyl]-N-(2-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 330784-94-6 USPATFULL


CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[3-(hydroxymethyl)-1-piperidiny]l]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 330784-95-7 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-cyano-4-methoxyphenyl)methyl]amino]-N-(trans-4-hydroxycyclohexyl)-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 330784-96-8 USPATFULL


CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-N-(trans-4-hydroxycyclohexyl)-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 330784-97-9 USPATFULL  
CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[4-formyl-3-(hydroxymethyl)-1-piperazinyl]-N-(trans-4-hydroxycyclohexyl)-(9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 330784-98-0 USPATFULL  
CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-N-(trans-4-hydroxycyclohexyl)-2-[(2R,4S)-4-hydroxy-2-(hydroxymethyl)-1-pyrrolidinyl]-, monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




● HCl

RN 330784-99-1 USPATFULL  
CN 1H-Imidazo[4,5-c]pyridine-6-carboxylic acid, 1-[4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-5-[[[(2-pyridinylmethyl)amino]carbonyl]-2-pyrimidinyl]-4,5,6,7-tetrahydro-, methyl ester (9CI) (CA INDEX NAME)



RN 330785-00-7 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[2-(hydroxymethyl)-1-piperidiny]]-N-(2-pyridinylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 330785-01-8 USPATFULL


CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(4-hydroxy-1-piperidiny]]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)





RN 330785-02-9 USPATFULL


CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[3-(hydroxymethyl)-1-piperidinyl]-N-(2-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)



RN 330785-03-0 USPATFULL


CN 5-Pyrimidinecarboxamide, 2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-4-[[[(4-methoxy-3-nitrophenyl)methyl]amino]-N-(2-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330785-04-1 USPATFULL


CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(1,3-dihydro-2H-isoindol-2-yl)-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



RN 330785-05-2 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-hydroxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-(2-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330785-06-3 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3,4-dichlorophenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-(2-pyrimidinylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330785-07-4 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-fluoro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-(2-pyrimidinylmethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330785-13-2 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-N-(trans-4-hydroxycyclohexyl)-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 330785-14-3 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(5,7-dihydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-N-(trans-4-hydroxycyclohexyl)- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 330785-15-4 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[3-(hydroxymethyl)-1-pyrrolidinyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 330785-16-5 USPATFULL


CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[3-(hydroxymethyl)-1-pyrrolidinyl]-N-(2-pyrimidinylmethyl)]- (9CI) (CA INDEX NAME)



RN 330785-17-6 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2R)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-(2-pyrimidinylmethyl)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330785-18-7 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-N-(1-ethyl-1H-pyrazol-5-yl)-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330785-19-8 USPATFULL


CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-pyrazinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 330785-20-1 USPATFULL  
CN 5-Pyrimidinecarboxamide, 4-[[[3-chloro-4-methoxyphenyl)methyl]amino]-2-  
[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-3-pyridinyl- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry..



RN 330785-21-2 USPATFULL  
CN 5-Pyrimidinecarboxamide, 4-[[[3-chloro-4-methoxyphenyl)methyl]amino]-2-  
[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-2-pyridinyl- (9CI) (CA INDEX  
NAME)


Absolute stereochemistry.



RN 330785-22-3 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-[(5-methyl-3-isoxazolyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 330785-23-4 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-N-[(4,6-dimethyl-2-pyrimidinyl)methyl]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 330785-24-5 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-2-thiazolyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330785-25-6 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-[(5-methylpyrazinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330785-26-7 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-(6-methoxy-2-benzothiazolyl)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330785-27-8 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-(5-methyl-3-isoxazolyl)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330785-28-9 USPTFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-[1-(methoxyacetyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330785-29-0 USPTFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-N-[(3,5-dimethyl-4-isoxazolyl)methyl]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330785-30-3 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-(2-quinolinylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330785-31-4 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-[(6-methyl-2-pyridinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330785-32-5 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-[(2-methyl-3-pyridinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330785-33-6 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-[(2-methyl-4-thiazolyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330785-34-7 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-1,3,4-thiadiazol-2-yl]- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 330785-35-8 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-(3-pyridazinylmethyl)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 330785-36-9 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-[(4-methoxy-2-pyrimidinyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330785-37-0 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-[trans-4-(2-pyrimidinyl)oxy]cyclohexyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330785-38-1 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-(4-methyl-2-thiazolyl)-(9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 330785-39-2 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-N-[(1,4-dihydro-6-methyl-4-oxo-2-pyrimidinyl)methyl]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 330785-40-5 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-N-[1-(cyanomethyl)-4-piperidinyl]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330785-41-6 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-N-[(2,5-dihydro-5-oxo-1H-pyrazol-3-yl)methyl]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330785-42-7 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-[(1-methyl-1H-pyrazol-4-yl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330785-43-8 USPATFULL


CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-(5-methyl-1H-pyrazol-3-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 330785-44-9 USPATFULL  
CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-  
[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-[(5-methyl-2-pyridinyl)methyl]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330785-45-0 USPATFULL  
CN 5-Pyrimidinecarboxamide, N-[(4-acetyl-2-pyrimidinyl)methyl]-4-[[[(3-chloro-  
4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330785-46-1 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-N-[[4-(hydroxymethyl)-2-pyrimidinyl]methyl]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330785-47-2 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[[(6-amino-3-pyridinyl)methyl]-4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330785-48-3 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-N-[[6-(hydroxymethyl)-2-pyridinyl]methyl]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330785-49-4 USPATFULL


CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-(1-methyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 330785-50-7 USPATFULL  
CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-1H-pyrazol-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330785-51-8 USPATFULL  
CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-formyl-1-pyrrolidinyl]-N-(2-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330785-52-9 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-(7-methoxy-3-quinolinyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330785-53-0 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-N-(3,5-dimethyl-1H-pyrazol-4-yl)-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330785-54-1 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2R,4R)-4-hydroxy-2-(hydroxymethyl)-1-pyrrolidinyl]-N-(2-pyrimidinylmethyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 330785-55-2 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-(3-methyl-1H-pyrazol-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 330785-56-3 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-N-(1,3-dimethyl-1H-pyrazol-4-yl)-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330785-57-4 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-N-(1,5-dimethyl-1H-pyrazol-4-yl)-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]]-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330785-58-5 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2R,3S)-3-hydroxy-2-(hydroxymethyl)-1-pyrrolidinyl]-N-(2-pyrimidinylmethyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 330785-59-6 USPATFULL

CN Phosphonic acid, [[[[4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-5-pyrimidinyl]carbonyl]amino]methyl]-, dimethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330785-65-4 USPATFULL

CN 5-Pyrimidinecarboxamide, 2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-4-[[4-methoxy-3-methylphenyl)methyl]amino]-N-(2-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 330785-66-5 USPATFULL

CN 5-Pyrimidinecarboxamide, 2,2'-(1,4-piperazinediyl)bis[4-[[3-chloro-4-methoxyphenyl)methyl]amino]-N-(trans-4-hydroxycyclohexyl)- (9CI) (CA INDEX NAME)

Relative stereochemistry.

PAGE 1-A




PAGE 1-B

OH

OMe

RN 330785-67-6 USPATFULL  
CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-  
[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-5-pyrimidinyl- (9CI) (CA  
INDEX NAME)


Absolute stereochemistry.



RN 330785-68-7 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-  
[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-2-pyrimidinyl- (9CI) (CA  
INDEX NAME)


Absolute stereochemistry.



RN 330785-69-8 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-  
[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-4-pyrimidinyl- (9CI) (CA  
INDEX NAME)


Absolute stereochemistry.



RN 330785-70-1 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-N-  
(3,4-dimethyl-5-isoxazolyl)-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330785-71-2 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-N-(4,6-dimethyl-2-pyridinyl)-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330785-72-3 USPATFULL


CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-N-(4,6-dimethyl-1-oxido-2-pyridinyl)-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 330785-73-4 USPATFULL  
CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-N-(4,6-dimethyl-2-pyrimidinyl)-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 330785-75-6 USPATFULL  
CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-[(2R)-4-methyl-2-morpholinyl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330785-76-7 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-[(2S)-4-methyl-2-morpholinyl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 330785-77-8 USPATFULL

CN 5-Pyrimidinecarboxamide, 2-[(2R,5S)-2,5-bis(hydroxymethyl)-1-pyrrolidinyl]-4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-N-(2-pyrimidinylmethyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.





RN 330785-79-0 USPATFULL  
CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L41 ANSWER 9 OF 18 USPATFULL  
ACCESSION NUMBER: 2002:323169 USPATFULL  
TITLE: 2, 4-disubstituted pyrimidine-5-carboxamide derivatives  
as KCNQ **potassium channel**  
modulators  
INVENTOR(S): Hewawasam, Piyasena, Middletown, CT, UNITED STATES  
Dodd, Dharmpal S., Princeton, NJ, UNITED STATES  
Weaver, Charles D., Wallingford, CT, UNITED STATES  
Dextraze, Pierre, Laprairie, CANADA  
Gribkoff, Valentin K., Wallingford, CT, UNITED STATES  
Kinney, Gene G., Collegeville, PA, UNITED STATES  
Dworetzky, Steven I., Middlefield, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002183335	A1	20021205
APPLICATION INFO.:	US 2002-75521	A1	20020214

*applicant's proxy*

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-269800P	20010220 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1346	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There is provided a method of treatment for disorders responsive to the modulation of KCNQ **potassium channels** by administering to a mammal in need thereof a therapeutically effective amount of a 2,4-disubstituted pyrimidine-5-carboxamide derivative of the Formula I ##STR1##

wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are as defined below. The present invention also provides pharmaceutical compositions comprising openers or activators of the KCNQ **potassium channels** and especially to the method of treatment of disorders sensitive to KCNQ **potassium channel** opening activity such as **migraine**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 452096-56-9P 452096-58-1P 452096-60-5P  
452096-62-7P 452096-64-9P 452096-66-1P  
452096-68-3P 452096-70-7P 452096-72-9P  
452096-74-1P 452096-76-3P 452096-78-5P  
452096-80-9P 452096-82-1P 452096-84-3P  
452096-86-5P 452096-88-7P 452096-90-1P  
452096-91-2P 452096-92-3P 452096-93-4P  
452096-94-5P 452096-95-6P 452096-96-7P  
452096-97-8P 452096-98-9P 452096-99-0P  
452097-00-6P 452097-01-7P 452097-02-8P  
452097-03-9P 452097-04-0P 452097-05-1P  
452097-06-2P 452097-07-3P 452097-08-4P  
452097-09-5P 452097-10-8P 452097-11-9P  
452097-12-0P 452097-13-1P 452097-14-2P  
452097-15-3P 452097-16-4P 452097-17-5P  
452097-18-6P 452097-19-7P 452097-20-0P  
452097-21-1P 452097-22-2P 452097-23-3P  
452097-24-4P 452097-25-5P 452097-26-6P  
452097-27-7P 452097-28-8P 452097-29-9P  
452097-30-2P 452097-31-3P 452097-32-4P  
452097-33-5P 452097-34-6P 452097-36-8P  
452097-38-0P 452097-39-1P 452097-40-4P  
452097-41-5P

(prepn. of 2,4-disubstituted pyrimidine-5-carboxamides as KCNQ **potassium channel** modulators)


RN 452096-56-9 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-cyclohexyl-N-[(4-fluorophenyl)methyl]-2-(4-morpholinyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 452096-55-8


CMF C22 H27 F N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 452096-58-1 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-cyclohexyl-2-(4-morpholinyl)-N-(phenylmethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 452096-57-0


CMF C22 H28 N4 O2



CM 2

CRN 76-05-1


CMF C2 H F3 O2




RN 452096-60-5 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-cyclohexyl-N-[(4-fluorophenyl)methyl]-2-(1-piperidinyl)-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 452096-59-2  
CMF C23 H29 F N4 O

CM 2


CRN 76-05-1  
CMF C2 H F3 O2RN 452096-62-7 USPATFULL  
CN 5-Pyrimidinecarboxamide, 4-cyclohexyl-N-[(4-fluorophenyl)methyl]-2-(1-pyrrolidinyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 452096-61-6  
CMF C22 H27 F N4 O

CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 452096-64-9 USPATFULL  
CN 5-Pyrimidinecarboxamide, 4-cyclohexyl-N-(cyclohexylmethyl)-2-[ethyl(phenylmethyl)amino]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 452096-63-8  
CMF C27 H38 N4 O



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 452096-66-1 USPATFULL  
CN 5-Pyrimidinecarboxamide, 4-cyclohexyl-2-[ethyl(phenylmethyl)amino]-N-(phenylmethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 452096-65-0  
CMF C27 H32 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 452096-68-3 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-cyclohexyl-2-[ethyl(phenylmethyl)amino]-N-[(4-fluorophenyl)methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 452096-67-2


CMF C27 H31 F N4 O



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 452096-70-7 USPATFULL  
CN 5-Pyrimidinecarboxamide, 4-cyclohexyl-N-(cyclohexylmethyl)-2-(2-methyl-1-piperidinyl)-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 452096-69-4  
CMF C24 H38 N4 O



CM 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 452096-72-9 USPATFULL  
CN 5-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-4-propyl-2-(1-pyrrolidinyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 452096-71-8  
CMF C19 H23 F N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 452096-74-1 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-2-(1-piperidinyl)-4-propyl-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 452096-73-0

CMF C20 H25 F N4 O




CM 2

CRN 76-05-1

CMF C2 H F3 O2






RN 452096-76-3 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-4-(1-methylethyl)-2-(1-pyrrolidinyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 452096-75-2


CMF C19 H23 F N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 452096-78-5 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-4-(1-methylethyl)-2-(1-piperidinyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 452096-77-4


CMF C20 H25 F N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 452096-80-9 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[(4-fluorophenyl)methyl]-4-(1-methylethyl)-2-(4-morpholinyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 452096-79-6


CMF C19 H23 F N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 452096-82-1 USPATFULL

CN 5-Pyrimidinecarboxamide, 2-[ethyl(phenylmethyl)amino]-4-(1-methylethyl)-N-(phenylmethyl)-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 452096-81-0


CMF C24 H28 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 452096-84-3 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-(2-fluorophenyl)-2-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 452096-83-2


CMF C23 H20 F4 N4 O



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 452096-86-5 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-(2-fluorophenyl)-2-(4-morpholinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 452096-85-4


CMF C23 H20 F4 N4 O2



CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 452096-88-7 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-(4-fluorophenyl)-2-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1

CRN 452096-87-6


CMF C23 H20 F4 N4 O




CM 2

CRN 76-05-1  
CMF C2 H F3 O2RN 452096-90-1 USPATFULL  
CN 5-Pyrimidinecarboxamide, 4-(2-fluorophenyl)-2-(4-morpholinyl)-N-[[3-(trifluoromethyl)phenyl]methyl]-, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1


CRN 452096-89-8  
CMF C23 H20 F4 N4 O2

CM 2

CRN 76-05-1  
CMF C2 H F3 O2


RN 452096-91-2 USPATFULL

CN 5-Pyrimidinecarboxamide, 2-(1-pyrrolidinyl)-4-(trifluoromethyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452096-92-3 USPATFULL

CN 5-Pyrimidinecarboxamide, 2-(1-pyrrolidinyl)-4-(trifluoromethyl)-N-[[3-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452096-93-4 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[(4-chlorophenyl)methyl]-2-(1-pyrrolidinyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 452096-94-5 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[(4-chlorophenyl)methyl]-2-(4-morpholinyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 452096-95-6 USPATFULL

CN 5-Pyrimidinecarboxamide, 2-(hexahydro-1H-azepin-1-yl)-N-[(4-methylphenyl)methyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 452096-96-7 USPATFULL

CN 5-Pyrimidinecarboxamide, 2-(1-pyrrolidinyl)-N-[[4-(trifluoromethoxy)phenyl]methyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 452096-97-8 USPATFULL

CN 5-Pyrimidinecarboxamide, 2-(4-morpholinyl)-N-[[4-(trifluoromethoxy)phenyl]methyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 452096-98-9 USPATFULL


CN 5-Pyrimidinecarboxamide, 2-(1-piperidinyl)-N-[[4-(trifluoromethoxy)phenyl]methyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 452096-99-0 USPATFULL


CN 5-Pyrimidinecarboxamide, 2-(diethylamino)-N-[[4-(trifluoromethoxy)phenyl]methyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)






RN 452097-00-6 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[(4-bromophenyl)methyl]-2-(1-pyrrolidinyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 452097-01-7 USPATFULL


CN 5-Pyrimidinecarboxamide, N-[[4-(dimethylamino)phenyl]methyl]-2-(1-pyrrolidinyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 452097-02-8 USPATFULL

CN 5-Pyrimidinecarboxamide, 2-(4-morpholinyl)-4-(trifluoromethyl)-N-[[4-  
[(trifluoromethyl)thio]phenyl]methyl]- (9CI) (CA INDEX NAME)


RN 452097-03-9 USPATFULL

CN 5-Pyrimidinecarboxamide, 2-amino-4-(1-pyrrolidinyl)-N-[[4-  
(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

RN 452097-04-0 USPATFULL


CN 5-Pyrimidinecarboxamide, 2-[(1-ethylpropyl)amino]-4-(1-pyrrolidinyl)-N-[[4-  
(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

RN 452097-05-1 USPATFULL

CN 5-Pyrimidinecarboxamide, 2-[ethyl(2-hydroxyethyl)amino]-4-(1-pyrrolidinyl)-  
N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)


RN 452097-06-2 USPATFULL

CN 5-Pyrimidinecarboxamide, 2-(methylpentylamino)-4-(1-pyrrolidinyl)-N-[[4-  
(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-07-3 USPATFULL

CN 5-Pyrimidinecarboxamide, 2,4-di-1-pyrrolidinyl-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-08-4 USPATFULL

CN 5-Pyrimidinecarboxamide, 2-(cyclopentylamino)-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-09-5 USPATFULL

CN 5-Pyrimidinecarboxamide, 2-[(phenylmethyl)amino]-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-10-8 USPATFULL

CN 5-Pyrimidinecarboxamide, 2-[methyl(phenylmethyl)amino]-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-11-9 USPATFULL

CN 5-Pyrimidinecarboxamide, 2-[(4-chlorophenyl)methylamino]-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-12-0 USPATFULL

CN 5-Pyrimidinecarboxamide, 2-(methyl-2-propynylamino)-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 452097-13-1 USPATFULL


CN 5-Pyrimidinecarboxamide, 2-(diethylamino)-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 452097-14-2 USPATFULL


CN 5-Pyrimidinecarboxamide, 2-[methyl[4-(trifluoromethoxy)phenyl]amino]-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-15-3 USPATFULL

CN 5-Pyrimidinecarboxamide, 2-[methyl(4-nitrophenyl)amino]-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-16-4 USPATFULL

CN 5-Pyrimidinecarboxamide, 2-(2-propynylamino)-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 452097-17-5 USPATFULL


CN 5-Pyrimidinecarboxamide, 2-[(3-chlorophenyl)methylamino]-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 452097-18-6 USPATFULL


CN 5-Pyrimidinecarboxamide, 2-[(3,4-dichlorophenyl)methylamino]-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)

pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-19-7 USPATFULL

CN 5-Pyrimidinecarboxamide, 2-(4-fluorophenoxy)-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-20-0 USPATFULL

CN 5-Pyrimidinecarboxamide, 2-(2-methoxyphenoxy)-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-21-1 USPATFULL

CN 5-Pyrimidinecarboxamide, 2-(2-propynyloxy)-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-22-2 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-(1-pyrrolidinyl)-2-(2-thienylmethoxy)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-23-3 USPATFULL

CN 5-Pyrimidinecarboxamide, 2-[2-(4-fluorophenyl)ethoxy]-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-24-4 USPATFULL

CN 5-Pyrimidinecarboxamide, 2-(3,4-dimethoxyphenyl)-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-25-5 USPATFULL

CN 5-Pyrimidinecarboxamide, 2-(2-methoxyphenyl)-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-26-6 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-(1-pyrrolidinyl)-2-(3-thienyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-27-7 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-(1-pyrrolidinyl)-2-(2-thienyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-28-8 USPATFULL

CN 5-Pyrimidinecarboxamide, 2-[[4-(4-chlorophenyl)methyl]thio]-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 452097-29-9 USPATFULL


CN 5-Pyrimidinecarboxamide, 2-[(2-furanylmethyl)thio]-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 452097-30-2 USPATFULL


CN 5-Pyrimidinecarboxamide, 2-[(4-nitrophenyl)thio]-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)






RN 452097-31-3 USPATFULL

CN 5-Pyrimidinecarboxamide, 2-[[4-(trifluoromethyl)phenyl]methylthio]-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-32-4 USPATFULL

CN 5-Pyrimidinecarboxamide, 2-[[2-chlorophenyl]thio]-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-33-5 USPATFULL

CN 5-Pyrimidinecarboxamide, 2-(cyclopropylthio)-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-34-6 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-(1-pyrrolidinyl)-2-(2-thienylthio)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-36-8 USPATFULL

CN 5-Pyrimidinecarboxamide, 2-[(2-methylpropyl)thio]-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-38-0 USPATFULL

CN 5-Pyrimidinecarboxamide, 2-[(phenylmethyl)thio]-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 452097-39-1 USPATFULL

CN 5-Pyrimidinecarboxamide, 2-(diethylamino)-N-[(5-methyl-2-furanyl)methyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 452097-40-4 USPATFULL

CN 5-Pyrimidinecarboxamide, N-(2-furanylmethyl)-2-(1-pyrrolidinyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 452097-41-5 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[(5-methyl-2-furanyl)methyl]-2-(4-morpholinyl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




IT 452097-47-1P 452097-48-2P

(prepn. of 2,4-disubstituted pyrimidine-5-carboxamides as KCNQ  
**potassium channel** modulators)


RN 452097-47-1 USPATFULL

CN 5-Pyrimidinecarboxamide, 2,4-dichloro-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 452097-48-2 USPATFULL

CN 5-Pyrimidinecarboxamide, 2-chloro-4-(1-pyrrolidinyl)-N-[[4-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)



L41 ANSWER 10 OF 18 USPATFULL

ACCESSION NUMBER: 2002:186284 USPATFULL

TITLE: 2,4,5,-trisubstituted pyrimidine derivatives

INVENTOR(S): Stadler, Heinz, Rheinfelden, SWITZERLAND

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002099207	A1	20020725
APPLICATION INFO.:	US 2001-977586	A1	20011015 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 2000-125529	20001122
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HOFFMANN-LA ROCHE INC.	PATENT LAW DEPARTMENT, 340 KINGSLAND STREET, NUTLEY, NJ, 07110
NUMBER OF CLAIMS:	35	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1834	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to compounds of the formula ##STR1##

wherein

R.sup.1 is lower alkyl, lower alkoxy, pyridinyl, pyrimidinyl, phenyl, --S-lower alkyl, --S(O).sub.2-lower alkyl, --N(R)--(CH.sub.2).sub.n--N(R).sub.2, --O--(CH.sub.2).sub.n--N(R).sub.2, --N(R).sub.2, or a cyclic tertiary amine of the group ##STR2##

which may contain one additional heteroatom, selected from N, O or S, and wherein this group may be connected with the pyrimidine ring via the linker --O(CH.sub.2).sub.n--;

R.sup.2 is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl;

R.sup.3/R.sup.3' is, independently from each other, hydrogen or lower alkyl;

R.sup.4 is independently from each other halogen, trifluoromethyl or lower alkoxy;

R.sup.5 is hydrogen or lower alkyl;

R is, independently from each other, hydrogen or lower alkyl;

X is --C(O)N(R)-- or --N(R)C(O)--;

Y is --O--, --S--, --SO.sub.2--, - or --N(R)--;

n is 1,2,3 or 4; and

m is 0,1 or 2;

or a pharmaceutically acceptable acid addition salt thereof. The compound of the invention has affinity to the NK1 receptor and is therefore suitable in the treatment of diseases related to this receptor.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 432520-78-OP 432520-86-OP 432521-20-5P

(prepn. of pyrimidine derivs. as NK1 antagonists)


RN 432520-78-0 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenoxy)-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 432520-86-0 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[(3,5-dimethoxyphenyl)methyl]-N-methyl-4-(2-methylphenoxy)-2-(methylthio)- (9CI) (CA INDEX NAME)



RN 432521-20-5 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[(3,5-bis(trifluoromethyl)phenyl)methyl]-N-methyl-4-(2-methylphenoxy)-2-(4-thiomorpholinyl)- (9CI) (CA INDEX NAME)




IT 432520-79-1P 432520-80-4P 432520-81-5P  
432520-82-6P 432520-83-7P 432520-84-8P  
432520-85-9P 432520-87-1P 432520-88-2P  
432520-89-3P 432520-90-6P 432520-91-7P  
432520-92-8P 432520-93-9P 432520-94-0P  
432520-95-1P 432520-96-2P 432520-97-3P  
432520-98-4P 432520-99-5P 432521-00-1P  
432521-01-2P 432521-02-3P 432521-03-4P  
432521-04-5P 432521-05-6P 432521-06-7P  
432521-07-8P 432521-08-9P 432521-09-0P  
432521-10-3P 432521-11-4P 432521-13-6P  
432521-14-7P 432521-15-8P 432521-16-9P  
432521-17-0P 432521-18-1P 432521-19-2P

**432521-21-6P**

(prepn. of pyrimidine derivs. as NK1 antagonists)


RN 432520-79-1 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenoxy)-2-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 432520-80-4 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenoxy)-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 432520-81-5 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenoxy)-2-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 432520-82-6 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenoxy)-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 432520-83-7 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[[2-(dimethylamino)ethyl]amino]-N-methyl-4-(2-methylphenoxy)- (9CI) (CA INDEX NAME)




RN 432520-84-8 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenoxy)-2-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 432520-85-9 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[2-(dimethylamino)ethoxy]-N-methyl-4-(2-methylphenoxy)- (9CI) (CA INDEX NAME)




RN 432520-87-1 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[(3,5-dimethoxyphenyl)methyl]-N-methyl-4-(2-methylphenoxy)-2-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 432520-88-2 USPATFULL


CN 5-Pyrimidinecarboxamide, N-[(3,5-dimethoxyphenyl)methyl]-N-methyl-4-(2-methylphenoxy)-2-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 432520-89-3 USPATFULL


CN 5-Pyrimidinecarboxamide, N-[(3,5-dimethoxyphenyl)methyl]-2-[2-(dimethylamino)ethoxy]-N-methyl-4-(2-methylphenoxy)- (9CI) (CA INDEX NAME)






RN 432520-90-6 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[(3,5-dimethylphenyl)methyl]-N-methyl-4-(2-methylphenoxy)-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 432520-91-7 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[(3,5-dimethylphenyl)methyl]-N-methyl-4-(2-methylphenoxy)-2-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 432520-92-8 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[(3,5-dimethylphenyl)methyl]-N-methyl-4-(2-methylphenoxy)-2-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 432520-93-9 USPATFULL

CN 5-Pyrimidinecarboxamide, 2-[2-(dimethylamino)ethoxy]-N-[(3,5-dimethylphenyl)methyl]-N-methyl-4-(2-methylphenoxy)- (9CI) (CA INDEX NAME)




RN 432520-94-0 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[(3,5-dichlorophenyl)methyl]-4-(2-methylphenoxy)-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 432520-95-1 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[(3,5-dichlorophenyl)methyl]-4-(2-methylphenoxy)-2-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 432520-96-2 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[(3,5-dichlorophenyl)methyl]-4-(2-methylphenoxy)-2-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 432520-97-3 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[(3,5-dichlorophenyl)methyl]-N-methyl-4-(2-methylphenoxy)-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 432520-98-4 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[(3,5-dichlorophenyl)methyl]-N-methyl-4-(2-methylphenoxy)-2-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 432520-99-5 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[(3,5-dichlorophenyl)methyl]-N-methyl-4-(2-methylphenoxy)-2-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 432521-00-1 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-2-(methylthio)-4-phenoxy- (9CI) (CA INDEX NAME)




RN 432521-01-2 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-2-(methylsulfonyl)-4-phenoxy- (9CI) (CA INDEX NAME)




RN 432521-02-3 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-2-(4-methyl-1-piperazinyl)-4-phenoxy- (9CI) (CA INDEX NAME)




RN 432521-03-4 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chlorophenoxy)-N-methyl-2-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 432521-04-5 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chlorophenoxy)-N-methyl-2-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 432521-05-6 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-methoxyphenoxy)-N-methyl-2-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 432521-06-7 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-methoxyphenoxy)-N-methyl-2-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 432521-07-8 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[[2-(dimethylamino)ethyl]amino]-4-(2-methoxyphenoxy)-N-methyl- (9CI) (CA INDEX NAME)




RN 432521-08-9 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(4-fluorophenoxy)-N-methyl-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 432521-09-0 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(4-fluorophenoxy)-N-methyl-2-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 432521-10-3 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(4-fluorophenoxy)-N-methyl-2-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 432521-11-4 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(4-fluorophenoxy)-N-methyl-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 432521-13-6 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[[2-(dimethylamino)ethyl]amino]-4-(4-fluorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 432521-14-7 USPATFULL


CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[2-(dimethylamino)ethoxy]-4-(4-fluorophenoxy)-N-methyl- (9CI) (CA INDEX NAME)



RN 432521-15-8 USPATFULL


CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenoxy)-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)






RN 432521-16-9 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(4-fluorophenoxy)-N-methyl-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 432521-17-0 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N,2-dimethyl-4-(2-methylphenoxy)- (9CI) (CA INDEX NAME)




RN 432521-18-1 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenoxy)-2-phenyl- (9CI) (CA INDEX NAME)




RN 432521-19-2 USPATFULL

CN [2,2'-Bipyrimidine]-5-carboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenoxy)- (9CI) (CA INDEX NAME)



RN 432521-21-6 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-(1,1-dioxido-4-thiomorpholinyl)-N-methyl-4-(2-methylphenoxy)- (9CI) (CA INDEX NAME)



L41 ANSWER 11 OF 18 USPATFULL

ACCESSION NUMBER: 2002:67175 USPATFULL

TITLE: ~~Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation~~

INVENTOR(S): Wilson, Leland F., Menlo Park, CA, UNITED STATES  
 Doherty, Paul C., JR., Cupertino, CA, UNITED STATES  
 Place, Virgil A., Kawaihae, HI, UNITED STATES  
 Smith, William L., Montclair, NJ, UNITED STATES  
 Abdel-Hamid Abdou Ali, Ibrahim AbouBakr, Mansoura, EGYPT

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002037828	A1	20020328
	US 6403597	B2	20020611
APPLICATION INFO.:	US 2001-888250	A1	20010621 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-467094, filed on 10 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1998-181070, filed on 27 Oct 1998, GRANTED, Pat. No. US 6037346 Continuation-in-part of Ser. No. US 1997-958816, filed on 28 Oct 1997, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	REED & ASSOCIATES, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025		
NUMBER OF CLAIMS:	94		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Page(s)		
LINE COUNT:	2011		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method is provided for treatment of premature ejaculation by administration of a phosphodiesterase inhibitor, e.g., an inhibitor of a Type III, Type IV, or Type V phosphodiesterase. In a preferred embodiment, administration is on as "as needed" basis, i.e., the drug is administered immediately or several hours prior to sexual activity. Pharmaceutical formulations and packaged kits are also provided.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 330784-28-6 330784-47-9 330785-79-0

(administration of phosphodiesterase inhibitors for treatment of premature ejaculation)

RN 330784-28-6 USPATFULL


CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-(5,8-dihydro-1,7-naphthyridin-7(6H)-yl)-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 330784-47-9 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-(2-pyrimidinylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 330785-79-0 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[[[(3-chloro-4-methoxyphenyl)methyl]amino]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]-N-(1,3,5-trimethyl-1H-pyrazol-4-yl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L41 ANSWER 12 OF 18 USPATFULL

ACCESSION NUMBER: 2002:27480 USPATFULL

TITLE: Corticotropin releasing factor antagonists

INVENTOR(S): ~~Chen~~ Yuhpyng L., Waterford, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002016328	A1	20020207
APPLICATION INFO.:	US 2001-761995	A1	20010117 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-176611P	20000118 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY, 10017-5612	

NUMBER OF CLAIMS: 22  
EXEMPLARY CLAIM: 1  
LINE COUNT: 5425

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Corticotropin-releasing factor (CRF) antagonists having the formulae  
##STR1##

wherein the dashed lines, A, B, Y, Z, G, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.16 and R.sub.17 are as defined in the application, and processes for preparing them. These compounds and their pharmaceutically acceptable salts are useful in the treatment disorders including CNS and stress-related disorders.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 351380-50-2P

(prepn. of pyridines, pyrimidines, purinones, pyrrolopyrimidinones and pyrrolopyridinones as corticotropin releasing factor antagonists)

RN 351380-50-2 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-(1-ethylpropoxy)-2-methyl-6-[(2,4,6-trimethylphenyl)amino]- (9CI) (CA INDEX NAME)



L41 ANSWER 13 OF 18 USPATFULL

ACCESSION NUMBER: 2001:131303 USPATFULL

TITLE: 4-phenyl-pyrimidine derivatives.

INVENTOR(S): Bos, Michael, Montreal, Canada  
Galley, Guido, Rheinfelden, Germany, Federal Republic of  
Godel, Thierry, Basel, Switzerland  
Hoffmann, Torsten, Birsfelden, Switzerland  
Hunkeler, Walter, Magden, Switzerland  
Schnider, Patrick, Oberwil, Switzerland  
Stadler, Heinz, Rheinfelden, Switzerland  
PATENT ASSIGNEE(S): Hoffmann-La Roche Inc., Nutley, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6274588	B1	20010814
APPLICATION INFO.:	US 2000-575382		20000522 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1999-110483	19990531
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Ford, John M.	
LEGAL REPRESENTATIVE:	Johnston, George W., Rocha-Tramaloni, Patricia S., Ebel, Eileen M.	
NUMBER OF CLAIMS:	11	

EXEMPLARY CLAIM: 1  
LINE COUNT: 2210  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
AB The invention provides compounds of the formula ##STR1##

wherein

R.sup.1 is hydrogen or halogen;

R.sup.2 is hydrogen, halogen, lower alkyl or lower alkoxy;

R.sup.1 and R.sup.2 may together be --CH.dbd.CH--CH.dbd.CH--, wherein R1 and R.sup.2 together with the two carbon ring atoms to which they are attached form a fused ring;

R.sup.3 is halogen, trifluoromethyl, lower alkyl or lower alkoxy;

R.sup.4 /R.sup.4' are each independently hydrogen or lower alkyl;

R.sup.5 is lower alkyl, lower alkoxy, amino, phenyl, hydroxy-lower alkyl, cyano-lower alkyl, carbamoyl-lower alkyl, pyridyl, pyrimidyl, --(CH.sub.2).sub.n -piperazinyl, which is optionally substituted by one or two lower alkyl groups or by hydroxy-lower alkyl, --(CH.sub.2).sub.n -morpholinyl, --(CH.sub.2).sub.n -piperidinyl, --(CH.sub.2).sub.n+1 -imidazolyl, lower alkyl-sulfanyl, lower alkyl-sulfonyl, benzylamino, --NH--(CH.sub.2).sub.n+1 N(R.sup.4").sub.2, --(CH.sub.2).sub.n+1 N(R.sup.4").sub.2, --O--(CH.sub.2).sub.n+1 -morpholinyl, --O--(CH.sub.2).sub.n+1 -piperidinyl or --O--(CH.sub.2).sub.n+1 N(R.sup.4").sub.2, wherein R.sup.4" is hydrogen or lower alkyl; and

n is 0-2;

X is --C(O)N(R.sup.4")-- or --N(R.sup.4")C(O)--;

and to pharmaceutically acceptable acid addition salts thereof.

It has been shown that the compounds have a good affinity to the NK-1 receptor and may therefore used for the treatment of diseases related to this receptor.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 311339-96-5P 311340-02-0P 311340-04-2P  
311340-12-2P 311340-13-3P 311340-14-4P  
311340-26-8P 311340-27-9P 311340-28-0P  
311340-34-8P 311340-38-2P 311340-39-3P  
311340-40-6P 311340-45-1P 311340-46-2P

(prepn and biol. activity of phenylpyrimidine derivs. as NK-1 antagonists)


RN 311339-96-5 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-bromophenyl)-N-methyl-2-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 311340-02-0 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chlorophenyl)-N-methyl-2-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 311340-04-2 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chlorophenyl)-N-methyl-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 311340-12-2 USPATFULL


CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-2-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 311340-13-3 USPATFULL


CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-N-methyl-4-(2-methylphenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 311340-14-4 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 311340-26-8 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(4-fluorophenyl)-N-methyl-2-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 311340-27-9 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-4-(4-fluorophenyl)-N-methyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.






RN 311340-28-0 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(4-fluorophenyl)-N-methyl-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 311340-34-8 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-fluorophenyl)-N-methyl-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 311340-38-2 USPATFULL


CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(4-fluoro-2-methylphenyl)-N-methyl-2-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 311340-39-3 USPATFULL


CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-4-(4-fluoro-2-methylphenyl)-N-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 311340-40-6 USPATFULL


CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(4-fluoro-2-methylphenyl)-N-methyl-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 311340-45-1 USPATFULL


CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-N-methyl-4-(1-naphthalenyl)-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 311340-46-2 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(1-naphthalenyl)-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)




IT 311339-57-8P 311339-58-9P 311339-59-0P  
311339-60-3P 311339-61-4P 311339-62-5P  
311339-63-6P 311339-64-7P 311339-65-8P  
311339-66-9P 311339-67-0P 311339-68-1P  
311339-69-2P 311339-70-5P 311339-71-6P  
311339-72-7P 311339-73-8P 311339-74-9P  
311339-75-0P 311339-76-1P 311339-77-2P  
311339-78-3P 311339-79-4P 311339-80-7P  
311339-81-8P 311339-82-9P 311339-83-0P  
311339-84-1P 311339-85-2P 311339-86-3P  
311339-87-4P 311339-88-5P 311339-89-6P  
311339-90-9P 311339-91-0P 311339-92-1P  
311339-93-2P 311339-94-3P 311339-95-4P  
311339-97-6P 311339-98-7P 311339-99-8P  
311340-00-8P 311340-01-9P 311340-03-1P  
311340-05-3P 311340-06-4P 311340-07-5P  
311340-08-6P 311340-09-7P 311340-10-0P  
311340-11-1P 311340-15-5P 311340-16-6P  
311340-17-7P 311340-18-8P 311340-19-9P  
311340-20-2P 311340-21-3P 311340-22-4P  
311340-23-5P 311340-24-6P 311340-25-7P  
311340-29-1P 311340-30-4P 311340-31-5P  
311340-32-6P 311340-33-7P 311340-35-9P  
311340-36-0P 311340-37-1P 311340-41-7P  
311340-42-8P 311340-43-9P 311340-44-0P  
311340-47-3P 311340-48-4P 311340-49-5P  
311340-50-8P 311340-51-9P 311340-52-0P

311340-53-1P 311340-55-3P 311340-56-4P  
311340-57-5P 311340-58-6P 311340-59-7P  
311340-60-0P 311340-61-1P 311340-62-2P  
311340-63-3P 311341-03-4P 311341-04-5P  
311341-05-6P 311341-06-7P 311341-07-8P  
311341-08-9P 311341-09-0P 311341-10-3P  
311341-11-4P 311341-12-5P 311341-13-6P  
311341-14-7P 311341-15-8P 311341-16-9P  
311341-17-0P

(prepn and biol. activity of phenylpyrimidine derivs. as NK-1 antagonists)


RN 311339-57-8 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N,2-dimethyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 311339-58-9 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[(3,5-dichlorophenyl)methyl]-N,2-dimethyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 311339-59-0 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-bromophenyl)-N,2-dimethyl- (9CI) (CA INDEX NAME)




RN 311339-60-3 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-bromophenyl)-2-methyl- (9CI) (CA INDEX NAME)




RN 311339-61-4 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-2,4-diphenyl- (9CI) (CA INDEX NAME)




RN 311339-62-5 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[(3,5-dichlorophenyl)methyl]-N-methyl-2,4-diphenyl- (9CI) (CA INDEX NAME)




RN 311339-63-6 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[(3,5-dichlorophenyl)methyl]-N-methyl-4-phenyl-2-propyl- (9CI) (CA INDEX NAME)




RN 311339-64-7 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-phenyl-2-propyl- (9CI) (CA INDEX NAME)




RN 311339-65-8 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-phenyl-2-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 311339-66-9 USPATFULL

CN [2,2'-Bipyrimidine]-5-carboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 311339-67-0 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-methyl-4-(1-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 311339-68-1 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N,2-dimethyl-4-(1-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 311339-69-2 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-methoxyphenyl)-N,2-dimethyl- (9CI) (CA INDEX NAME)




RN 311339-70-5 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-2-(methylthio)-4-phenyl- (9CI) (CA INDEX NAME)




RN 311339-71-6 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-2-(methylsulfonyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 311339-72-7 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-2-(4-methyl-1-piperazinyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 311339-73-8 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-phenyl-2-[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 311339-74-9 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-2-(4-morpholinyl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 311339-75-0 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-phenyl-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 311339-76-1 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-N-methyl-4-phenyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.






RN 311339-77-2 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[[2-(dimethylamino)ethyl]amino]-N-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 311339-78-3 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-phenyl-2-(1-piperidinyl)- (9CI) (CA INDEX NAME)



RN 311339-79-4 USPATFULL


CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[4-(2-hydroxyethyl)-1-piperazinyl]-N-methyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 311339-80-7 USPATFULL


CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-

methyl-2-[2-(4-morpholinyl)ethoxy]-4-phenyl- (9CI) (CA INDEX NAME)




RN 311339-81-8 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-phenyl-2-[2-(1-piperidinyloxy)- (9CI) (CA INDEX NAME)




RN 311339-82-9 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[2-(dimethylamino)ethoxy]-N-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 311339-83-0 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[3-(dimethylamino)propoxy]-N-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 311339-84-1 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-methoxy-N-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 311339-85-2 USPATFULL

CN 2-Pyrimidineacetamide, 5-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 311339-86-3 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-(cyanomethyl)-N-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 311339-87-4 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-(hydroxymethyl)-N-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 311339-88-5 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[(dimethylamino)methyl]-N-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 311339-89-6 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-2-(4-morpholinylmethyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 311339-90-9 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-2-[(4-methyl-1-piperazinyl)methyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 311339-91-0 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-phenyl-2-(1-piperidinylmethyl)- (9CI) (CA INDEX NAME)




RN 311339-92-1 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-(1H-imidazol-1-ylmethyl)-N-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 311339-93-2 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-bromophenyl)-N-methyl-2-(methylthio)- (9CI) (CA INDEX NAME)



RN 311339-94-3 USPATFULL


CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-bromophenyl)-N-methyl-2-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 311339-95-4 USPATFULL

CN 5-Pyrimidinecarboxamide, 2-amino-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-bromophenyl)-N-methyl-2-(methylsulfonyl)- (9CI) (CA INDEX NAME)


] -4-(2-bromophenyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 311339-97-6 USPATFULL


CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-bromophenyl)-2-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-N-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 311339-98-7 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-bromophenyl)-N-methyl-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 311339-99-8 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-bromophenyl)-N-methyl-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 311340-00-8 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chlorophenyl)-N-methyl-2-(methylthio)- (9CI) (CA INDEX NAME)



RN 311340-01-9 USPATFULL


CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chlorophenyl)-N-methyl-2-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 311340-03-1 USPATFULL


CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chlorophenyl)-2-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-N-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 311340-05-3 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chlorophenyl)-N-methyl-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 311340-06-4 USPATFULL


CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chlorophenyl)-2-[[2-(dimethylamino)ethyl]amino]-N-methyl- (9CI) (CA INDEX NAME)



RN 311340-07-5 USPATFULL


CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chlorophenyl)-N-methyl-2-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)






RN 311340-08-6 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chlorophenyl)-2-[2-(dimethylamino)ethoxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 311340-09-7 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chlorophenyl)-2-[3-(dimethylamino)propoxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 311340-10-0 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 311340-11-1 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-2-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 311340-15-5 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 311340-16-6 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[2-(dimethylamino)ethoxy]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 311340-17-7 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[3-(dimethylamino)propoxy]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 311340-18-8 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-methoxyphenyl)-N-methyl-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 311340-19-9 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-methoxyphenyl)-N-methyl-2-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 311340-20-2 USPATFULL


CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-methoxyphenyl)-N-methyl-2-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 311340-21-3 USPATFULL


CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-4-(2-methoxyphenyl)-N-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 311340-22-4 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-methoxyphenyl)-N-methyl-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 311340-23-5 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-methoxyphenyl)-N-methyl-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 311340-24-6 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(4-fluorophenyl)-N-methyl-2-(methylthio)- (9CI) (CA INDEX NAME)



RN 311340-25-7 USPATFULL


CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(4-fluorophenyl)-N-methyl-2-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 311340-29-1 USPATFULL


CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(4-

fluorophenyl)-N-methyl-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 311340-30-4 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-fluorophenyl)-N-methyl-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 311340-31-5 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-fluorophenyl)-N-methyl-2-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 311340-32-6 USPATFULL


CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-fluorophenyl)-N-methyl-2-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)



RN 311340-33-7 USPATFULL


CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-4-(2-fluorophenyl)-N-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 311340-35-9 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-fluorophenyl)-N-methyl-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 311340-36-0 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(4-fluoro-2-methylphenyl)-N-methyl-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 311340-37-1 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(4-fluoro-2-methylphenyl)-N-methyl-2-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 311340-41-7 USPATFULL


CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(4-fluoro-2-methylphenyl)-N-methyl-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 311340-42-8 USPATFULL


CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-2-(methylthio)-4-(1-naphthalenyl)- (9CI) (CA INDEX NAME)






RN 311340-43-9 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-2-(methylsulfonyl)-4-(1-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 311340-44-0 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-2-(4-methyl-1-piperazinyl)-4-(1-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 311340-47-3 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-2-(4-morpholinyl)-4-(1-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 311340-48-4 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-phenyl-2-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 311340-49-5 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chloro-4-fluorophenyl)-N-methyl-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 311340-50-8 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chloro-4-fluorophenyl)-N-methyl-2-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 311340-51-9 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chloro-4-fluorophenyl)-N-methyl-2-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 311340-52-0 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chloro-4-fluorophenyl)-N-methyl-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 311340-53-1 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chloro-4-fluorophenyl)-N-methyl-2-(1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 311340-55-3 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chloro-4-fluorophenyl)-2-[2-(dimethylamino)ethoxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 311340-56-4 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chloro-4-fluorophenyl)-2-[3-(dimethylamino)propoxy]-N-methyl- (9CI) (CA INDEX NAME)




RN 311340-57-5 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chloro-4-fluorophenyl)-N-methyl-2-[2-(4-morpholinyl)ethoxy]- (9CI) (CA INDEX NAME)




RN 311340-58-6 USPATFULL


CN 5-Pyrimidinecarboxamide, N-[(3,5-dimethoxyphenyl)methyl]-N-methyl-4-(2-methylphenyl)-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 311340-59-7 USPATFULL  
CN 5-Pyrimidinecarboxamide, N-[(3,5-dimethoxyphenyl)methyl]-N-methyl-4-(2-methylphenyl)-2-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 311340-60-0 USPATFULL  
CN 5-Pyrimidinecarboxamide, N-[(3,5-dimethoxyphenyl)methyl]-N-methyl-4-(2-methylphenyl)-2-(4-methyl-1-piperazinyl)- (9CI) (CA INDEX NAME)




RN 311340-61-1 USPATFULL  
CN 5-Pyrimidinecarboxamide, N-[(3,5-dimethoxyphenyl)methyl]-N-methyl-4-(2-methylphenyl)-2-(4-morpholinyl)- (9CI) (CA INDEX NAME)




RN 311340-62-2 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[(3,5-dimethoxyphenyl)methyl]-2-[[2-(dimethylamino)ethyl]amino]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)



RN 311340-63-3 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[(3,5-dimethoxyphenyl)methyl]-2-[2-(dimethylamino)ethoxy]-N-methyl-4-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 311341-03-4 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-bromophenyl)-N-methyl-2-(4-methyl-1-piperazinyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 311339-96-5


CMF C26 H24 Br F6 N5 O



CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E


Double bond geometry as shown.



RN 311341-04-5 USPATFULL  
CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chlorophenyl)-N-methyl-2-(4-methyl-1-piperazinyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 311340-02-0  
CMF C26 H24 Cl F6 N5 O



CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E


Double bond geometry as shown.



RN 311341-05-6 USPATFULL  
CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-chlorophenyl)-N-methyl-2-(1-piperazinyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 311340-04-2  
CMF C25 H22 Cl F6 N5 O




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.




RN 311341-06-7 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-2-(4-methyl-1-piperazinyl)-,  
 (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 311340-12-2

CMF C27 H27 F6 N5 O




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.



RN 311341-07-8 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-  
 [(3R,5S)-3,5-dimethyl-1-piperazinyl]-N-methyl-4-(2-methylphenyl)-, rel-,  
 (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)




CM 1

CRN 311340-13-3

CMF C28 H29 F6 N5 O

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.




RN 311341-08-9 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(2-methylphenyl)-2-(1-piperazinyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 311340-14-4

CMF C26 H25 F6 N5 O




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.




RN 311341-09-0 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(4-fluorophenyl)-N-methyl-2-(4-methyl-1-piperazinyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 311340-26-8

CMF C26 H24 F7 N5 O




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.



RN 311341-10-3 USPATFULL


CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-[(3R,5S)-3,5-dimethyl-1-piperazinyl]-4-(4-fluorophenyl)-N-methyl-, rel-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 311340-27-9

CMF C27 H26 F7 N5 O

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.




RN 311341-11-4 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(4-fluorophenyl)-N-methyl-2-(1-piperazinyl)-, (2E)-2-butenedioate (1:1)  
(9CI) (CA INDEX NAME)

CM 1

CRN 311340-28-0

CMF C25 H22 F7 N5 O




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.




RN 311341-12-5 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(2-fluorophenyl)-N-methyl-2-(1-piperazinyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 311340-34-8

CMF C25 H22 F7 N5 O




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.




RN 311341-13-6 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(4-fluoro-2-methylphenyl)-N-methyl-2-(4-methyl-1-piperazinyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 311340-38-2

CMF C27 H26 F7 N5 O




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.



RN 311341-14-7 USPATFULL


CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-  
[(3R,5S)-3,5-dimethyl-1-piperazinyl]-4-(4-fluoro-2-methylphenyl)-N-  
methyl-, rel-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 311340-39-3

CMF C28 H28 F7 N5 O

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.




RN 311341-15-8 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-(4-  
fluoro-2-methylphenyl)-N-methyl-2-(1-piperazinyl)-, (2E)-2-butenedioate  
(1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 311340-40-6

CMF C26 H24 F7 N5 O




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E

Double bond geometry as shown.



RN 311341-16-9 USPATFULL


CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-  
 [(3R,5S)-3,5-dimethyl-1-piperazinyl]-N-methyl-4-(1-naphthalenyl)-, rel-,  
 (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 311340-45-1

CMF C31 H29 F6 N5 O

Relative stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

CDES 2:E


Double bond geometry as shown.



RN 311341-17-0 USPATFULL  
CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-methyl-4-(1-naphthalenyl)-2-(1-piperazinyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 311340-46-2  
CMF C29 H25 F6 N5 O



CM 2

CRN 110-17-8  
CMF C4 H4 O4  
CDES 2:E


Double bond geometry as shown.



IT 311340-71-3P 311340-75-7P 311340-82-6P  
311340-83-7P 311340-84-8P 311340-86-0P  
311340-87-1P


(prepn and biol. activity of phenylpyrimidine derivs. as NK-1 antagonists)

RN 311340-71-3 USPATFULL  
CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 311340-75-7 USPATFULL  
CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-N-

methyl-2-[(methanesulfonyl)methyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 311340-82-6 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[(3,5-dichlorophenyl)methyl]-2-methyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 311340-83-7 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2,4-diphenyl- (9CI) (CA INDEX NAME)



RN 311340-84-8 USPATFULL


CN 5-Pyrimidinecarboxamide, N-[(3,5-dichlorophenyl)methyl]-2,4-diphenyl- (9CI) (CA INDEX NAME)



RN 311340-86-0 USPATFULL


CN 5-Pyrimidinecarboxamide, N-[(3,5-dichlorophenyl)methyl]-4-phenyl-2-propyl- (9CI) (CA INDEX NAME)





RN 311340-87-1 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-4-phenyl-2-propyl- (9CI) (CA INDEX NAME)



L41 ANSWER 14 OF 18 USPATFULL

ACCESSION NUMBER: 2000:153716 USPATFULL

TITLE: Azospiro compounds as NK1 or NK2 antagonists

INVENTOR(S): Russell, Keith, Newark, DE, United States

PATENT ASSIGNEE(S): Zeneca Limited, United Kingdom (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	<u>US 6147083</u>		20001114
APPLICATION INFO.:	US 1999-384444		<u>19990827</u> (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-979995, filed on 26 Nov 1997, now patented, Pat. No. US 5998444 which is a continuation of Ser. No. US 1995-547512, filed on 24 Oct 1995, now patented, Pat. No. US 5710169		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1994-21411	19941025
	GB 1995-12367	19950617
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Chang, Ceila	
LEGAL REPRESENTATIVE:	Person, Richard V.	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1761	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of formula I: ##STR1## wherein Q.sup.1, Q.sup.2, Q.sup.3, Q.sup.4, and Q.sup.5 have any of the meanings given in the specification, their N-oxides, and their pharmaceutically acceptable salts are nonpeptide antagonists of SP and NKA are useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 178166-76-2P

(prepn. of N-acylated 2-heterocycloethylamines as nonpeptide antagonists of SP and NKA)

RN 178166-76-2 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[2-(3,4-dichlorophenyl)-2-(4-hydroxy-4-phenyl-1-piperidinyl)ethyl]-1,2,3,4-tetrahydro-N-methyl-2,4-dioxo- (9CI) (CA INDEX NAME)



L41 ANSWER 15 OF 18 USPATFULL

ACCESSION NUMBER: 1999:160060 USPATFULL

TITLE: Piperidinyl compounds as NK1 or NK2 antagonists

INVENTOR(S): Russell, Keith, Newark, DE, United States

PATENT ASSIGNEE(S): Zeneca Ltd., United Kingdom (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5998444		19991207
APPLICATION INFO.:	US 1997-979995		19971126 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-547512, filed on 24 Oct 1995, now patented, Pat. No. US 5710169		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Chang, Ceila		
LEGAL REPRESENTATIVE:	Person, Richard V.		
NUMBER OF CLAIMS:	12		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1769		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of formula I ##STR1## wherein Q.sup.1, Q.sup.2, Q.sup.3, Q.sup.4, and Q.sup.5 have any of the meanings given in the specification, their N-oxides, and their pharmaceutically acceptable salts are nonpeptide antagonists of SP and NKA are useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 178166-76-2P

(prepn. of N-acylated 2-heterocycloethylamines as nonpeptide antagonists of SP and NKA)

RN 178166-76-2 USPATFULL

CN 5-Pyrimidinecarboxamide, N-[2-(3,4-dichlorophenyl)-2-(4-hydroxy-4-phenyl-1-piperidinyl)ethyl]-1,2,3,4-tetrahydro-N-methyl-2,4-dioxo- (9CI) (CA INDEX NAME)



L41 ANSWER 16 OF 18 USPATFULL

ACCESSION NUMBER:

1998:160118 USPATFULL

TITLE:

Diazepinoindoles as phosphodiesterase IV inhibitors

INVENTOR(S):

Pascal, Yves, Rueil-Malmaison, France

Moodley, Indres, Versailles, France

Calvet, Alain, L'Hay-les-Roses, France

Junien, Jean-Louis, Sevres, France

PATENT ASSIGNEE(S):

Institut de Recherche Jouveinal SA, Fresnes, France  
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5852190		19981222
APPLICATION INFO.:	US 1995-391865		19950222 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1994-12282	19941014
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Ford, John M.	
LEGAL REPRESENTATIVE:	Crissey, Todd M.	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1415	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to diazepinoindoles of formula: ##STR1## in which R is hydrogen, lower alkyl or lower alkoxy; A is aryl or nitrogen-containing heteroaryl, each of which is optionally substituted by from one to three groups of halogen, lower alkyl, haloalkyl, lower alkoxy and acetamido, or their racemic forms, isomers or pharmaceutically acceptable salts, wherein for the racemic forms of the (S) configuration, A is not phenyl, haloalkyl, or 2-indolyl when R is hydrogen, and for the racemic forms of the (R) configuration, A is not 2-indolyl when R is hydrogen. Also, the invention relates to a method for inhibiting cyclic nucleotide phosphodiesterase activity by administering these compounds to a subject in an amount which is therapeutically effective to inhibit cyclic nucleotide phosphodiesterase activity.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 179023-76-8P

(prepn. of diazepinoindoles as phosphodiesterase IV inhibitors)

RN 179023-76-8 USPATFULL

CN 5-Pyrimidinecarboxamide, 2-chloro-N-(3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl)-4-(trifluoromethyl)-  
(9CI) (CA INDEX NAME)



L41 ANSWER 17 OF 18 USPATFULL

ACCESSION NUMBER: 1998:7087 USPATFULL

TITLE: Therapeutic heterocycles

INVENTOR(S): Russell, Keith, Newark, DE, United States

PATENT ASSIGNEE(S): Zeneca Limited, London, United Kingdom (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5710169		19980120
APPLICATION INFO.:	US 1995-547512		19951024 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1994-21411	19941025
	GB 1995-12367	19950617
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Ivy, C. Warren	
ASSISTANT EXAMINER:	Dahlen, Garth M.	
LEGAL REPRESENTATIVE:	Harris, Robert J., Darkes, Paul R.	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1866	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of formula I ##STR1## wherein Q.sup.1, Q.sup.2, Q.sup.3, Q.sup.4, and Q.sup.5 have any of the meanings given in the specification, their N-oxides, and their pharmaceutically acceptable salts are nonpeptide antagonists of SP and NKA are useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 178166-76-2P

(prepn. of N-acylated 2-heterocycloethylamines as nonpeptide antagonists of SP and NKA)


RN 178166-76-2 USPATFULL


CN 5-Pyrimidinecarboxamide, N-[2-(3,4-dichlorophenyl)-2-(4-hydroxy-4-phenyl-1-piperidinyl)ethyl]-1,2,3,4-tetrahydro-N-methyl-2,4-dioxo- (9CI) (CA INDEX NAME)



RN 157360-94-6 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[butyl[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]amino]-N-methoxy-2-methyl- (9CI) (CA INDEX NAME)





L41 ANSWER 18 OF 18 USPATFULL

ACCESSION NUMBER:

93:82865 USPATFULL

TITLE:

Angiotensin II receptor antagonists

INVENTOR(S):

Winn, Martin, Deerfield, IL, United States  
De, Biswanath, Buffalo Grove, IL, United States  
Zydowsky, Thomas M., Waukegan, IL, United States  
Kerkman, Daniel J., Lake Villa, IL, United States  
DeBernardis, John F., Lindenhurst, IL, United States  
Rosenberg, Saul H., Libertyville, IL, United States  
Shiosaki, Kazumi, Libertyville, IL, United States  
Basha, Fatima Z., Lake Forest, IL, United States  
Tasker, Andrew S., Lindenhurst, IL, United States  
von Geldern, Thomas W., Richmond, IL, United States  
Kester, Jeffrey A., Deerfield, IL, United States  
Boyd, Steven, Mundelein, IL, United States  
Yamamoto, Diane M., Gurnee, IL, United States  
Fung, Anthony K. L., Gurnee, IL, United States  
Abbott Laboratories, Abbott Park, IL, United States  
(U.S. corporation)

PATENT ASSIGNEE(S):

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5250548		19931005
APPLICATION INFO.:	US 1992-844351		19920302 (7)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1991-744241, filed on 15 Aug 1991 which is a continuation-in-part of Ser. No. US 1990-580400, filed on 10 Sep 1990, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Ford, John M.		
ASSISTANT EXAMINER:	Gupta, Y. N.		
LEGAL REPRESENTATIVE:	Crowley, Steven R.		
NUMBER OF CLAIMS:	16		
EXEMPLARY CLAIM:	1		
LINE COUNT:	7545		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds are disclosed having the formula: ##STR1## The compounds of the invention are angiotensin II receptor antagonists.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 141871-62-7P 157360-94-6P  
(prepn. of)

RN 141871-62-7 USPATFULL

CN 5-Pyrimidinecarboxamide, 4-[butyl[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]amino]-2-methyl- (9CI) (CA INDEX NAME)

=> fil toxcenter

FILE 'TOXCENTER' ENTERED AT 15:02:15 ON 08 MAY 2003  
COPYRIGHT (C) 2003 ACS

FILE COVERS 1907 TO 6 May 2003 (20030506/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

TOXCENTER has been enhanced with new files segments and search fields.  
See HELP CONTENT for more information.

TOXCENTER thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2003 vocabulary. See <http://www.nlm.nih.gov/mesh/summ2003.html> for a description on changes.

=> d que nos 132; fil biosis

L1 STR  
L3 4706 SEA FILE=REGISTRY SSS FUL L1  
L17 1052 SEA FILE=REGISTRY ABB=ON L3 AND TOXCENTER/LC  
L29 128 SEA FILE=TOXCENTER ABB=ON L17  
L30 8792 SEA FILE=TOXCENTER ABB=ON (POTASSIUM(3A)CHANNEL?)  
L31 19073 SEA FILE=TOXCENTER ABB=ON HEADACHE# OR MIGRAINE# OR ANTIMIGRAI  
NE# OR STATUS MIGRAINOSUS OR HEMICRANIA  
L32 0 SEA FILE=TOXCENTER ABB=ON L29 AND (L30 OR L31)

FILE 'BIOSIS' ENTERED AT 15:02:21 ON 08 MAY 2003  
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE COVERS 1969 TO DATE.  
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT  
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 7 May 2003 (20030507/ED)

=> d que nos 134; fil drugu; d que nos 136; fil medl; d que nos 139; fil cao; s 13

L1 STR  
L3 4706 SEA FILE=REGISTRY SSS FUL L1  
L16 2 SEA FILE=REGISTRY ABB=ON L3 AND BIOSIS/LC  
L26 3 SEA FILE=BIOSIS ABB=ON L16  
L33 55107 SEA FILE=BIOSIS ABB=ON HEADACHE# OR MIGRAINE# OR ANTIMIGRAINE#  
OR STATUS MIGRAINOSUS OR (POTASSIUM(3A)CHANNEL?)  
L34 0 SEA FILE=BIOSIS ABB=ON L26 AND L33

FILE 'DRUGU' ENTERED AT 15:02:39 ON 08 MAY 2003  
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE LAST UPDATED: 7 MAY 2003 <20030507/UP>

>>> DERWENT DRUG FILE (SUBSCRIBER) <<<

>>> SDI'S MAY BE RUN WEEKLY OR MONTHLY AS OF JUNE 2001. <<<

>>> (WEEKLY IS THE DEFAULT). FOR PRICING INFORMATION <<<

>>> SEE HELP COST <<<

>>> FILE COVERS 1983 TO DATE <<<

>>> THESAURUS AVAILABLE IN /CT <<<

```
L1          STR
L3          4706 SEA FILE=REGISTRY SSS FUL L1
L15         1 SEA FILE=REGISTRY ABB=ON L3 AND DRUGU/LC
L25         2 SEA FILE=DRUGU ABB=ON L15
L35         33531 SEA FILE=DRUGU ABB=ON HEADACHE# OR MIGRAINE# OR ANTIMIGRAINE#
              OR STATUS MIGRAINOSUS OR (POTASSIUM(3A)CHANNEL?)
L36         0 SEA FILE=DRUGU ABB=ON L25 AND L35
```

FILE 'MEDLINE' ENTERED AT 15:02:40 ON 08 MAY 2003

FILE LAST UPDATED: 7 MAY 2003 (20030507/UP). FILE COVERS 1958 TO DATE.

On April 13, 2003, MEDLINE was reloaded. See HELP RLOAD for details.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2003 vocabulary. See <http://www.nlm.nih.gov/mesh/changes2003.html> for a description on changes.

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
L1          STR
L3          4706 SEA FILE=REGISTRY SSS FUL L1
L13         1 SEA FILE=REGISTRY ABB=ON L3 AND MEDLINE/LC
L24         3 SEA FILE=MEDLINE ABB=ON L13
L37         12594 SEA FILE=MEDLINE ABB=ON VASCULAR HEADACHES+NT/CT
L38         16772 SEA FILE=MEDLINE ABB=ON POTASSIUM CHANNELS+NT/CT
L39         0 SEA FILE=MEDLINE ABB=ON (L37 OR L38) AND L24
```

FILE 'CAOLD' ENTERED AT 15:02:40 ON 08 MAY 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966

FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

```
L42         84 L3
```

```
=> d que nos 144; fil hom
```

```
L1          STR
L3          4706 SEA FILE=REGISTRY SSS FUL L1
L42         84 SEA FILE=CAOLD ABB=ON L3
```



L43 113 SEA FILE=CAOLD ABB=ON HEADACHE# OR MIGRAINE# OR ANTIMIGRAINE#  
OR STATUS MIGRAINOSUS OR (POTASSIUM(3A)CHANNEL?)  
L44 0 SEA FILE=CAOLD ABB=ON L42 AND L43

FILE 'HOME' ENTERED AT 15:03:30 ON 08 MAY 2003

**THIS PAGE BLANK (USPTO)**